Respiratory syncytial virus mRNA vaccine and preparation method and application thereof
By designing an mRNA vaccine encoding the pre-fusion conformation of RSV F protein, using specific amino acid mutations and lipid nanoparticle carriers, the problem of poor prevention effect of traditional RSV vaccines in low-immune populations is solved, achieving high stability and strong Immune response, suitable for a variety of RSV subtypes.
Patent Information
- Application Number
- CN202410911569.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-07-09
AI Technical Summary
The existing RSV vaccines are difficult to effectively prevent respiratory syncytial virus infection in low-immune populations, especially in children and the elderly, and traditional vaccines have stability and safety problems, such as disease enhancement and adverse reactions.
An mRNA vaccine encoding the conformation of the RSV F protein was designed. Through specific amino acid mutations and modifications, the stability and immune response effect of the vaccine are improved, including mutations such as P102A, I379V and M447V, and combined with lipid nanoparticles as carriers. agents used to enhance the antigen epitope specificity and stability of vaccines.
It significantly improves humoral immune effect, enhances the production of neutralizing antibodies against RSV, reduces inflammatory response and viral load, is suitable for a variety of RSV subtypes, and has high safety and stability.
Smart Images

Figure CN118480560B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nucleic acid vaccines, and specifically relates to a respiratory syncytial virus mRNA vaccine and a preparation method and application thereof. Background Art
[0002] Respiratory syncytial virus (RSV) is a negative-sense single-stranded RNA virus of the genus Pneumovirus in the family Paramyxoviridae. In 1956, scientists isolated RSV from chimpanzee respiratory specimens. RSV was named respiratory syncytial virus because it causes adjacent cells to fuse during cell culture and the cells transform into a syncytium-like structure.
[0003] RSV is an important pathogen that causes lower respiratory tract infections in infants, the elderly, and immunocompromised patients. RSV is transmitted through the air and enters the trachea and lungs through the mouth and nose. It invades epithelial cells and causes airway damage. The respiratory mucus secreted on the airway surface blocks the lumen and causes breathing difficulties. Common symptoms of RSV infection are runny nose, fever, cough, and asthma. In severe cases, it can cause respiratory distress and even airway obstruction, leading to respiratory failure or even death.
[0004] RSV is a common respiratory virus. It usually causes cold-like symptoms. RSV infection mainly occurs in the fall, winter and spring, and is one of the main causes of severe respiratory diseases in infants under 5 years old and the elderly over 65 years old. For most young people, RSV usually causes mild, cold-like symptoms, but for infants and the elderly, RSV infection is a fatal disease.
[0005] RSV infection has become a global public health problem. RSV is the most common viral pathogen causing acute lower respiratory tract infections (ALRTI) in children under 5 years old worldwide, and is the primary factor causing hospitalization for viral respiratory tract infections in infants and young children. Data show that RSV infection accounts for 28% of all ALRTIs, of which RSV hospitalized deaths account for 13%-22% of ALRTI-related deaths.
[0006] RSV infection is a global epidemic, and its prevalence is affected by factors such as geographical location, temperature and humidity. For example, the RSV epidemic season in northern my country starts from mid-October to mid-May of the following year, and it is more common in winter and spring in southern China, which is closely related to temperature. RSV has only one serotype, which is divided into two subtypes, A and B, and it is alternating in northern my country.
[0007] Vaccines are the most economical and effective prevention and treatment measure for RSV infection. WHO lists the development of RSV vaccines as one of the urgent issues that need to be addressed. However, the development of RSV vaccines has been carried out since the 1960s, and no effective vaccine certified by regulatory agencies has been approved for marketing. Recently, RSV vaccines have made major breakthroughs. On May 3, 2023, the respiratory syncytial virus (RSV) vaccine Arexvy developed by GSK was approved for marketing by the FDA, becoming the world's first approved RSV vaccine. The vaccine is mainly used for patients aged 60 and above to prevent lower respiratory tract (bronchial and lung) diseases caused by RSV infection. Subsequently, on June 1, 2023, the US FDA approved Pfizer's RSV protein vaccine Abrysvo TM It is marketed for the prevention of acute respiratory and lower respiratory tract diseases caused by RSV in adults aged 60 years and above.
[0008] The current RSV vaccine technology routes under development include live attenuated vaccines, subunit vaccines, recombinant vector vaccines, and mRNA vaccines. Traditional vaccines are usually based on inactivated or attenuated live virus vaccines, or subunit proteins derived from pathogens. Although these vaccines produce effective immune responses, they have many related safety issues. For example, the early-developed RSV inactivated vaccine not only failed to protect the vaccine recipients, but also showed disease enhancement (ERD), that is, it not only failed to prevent the vaccine recipients from being infected with the RSV virus, but also caused the vaccine recipients to become more seriously ill after being infected with RSV. In a clinical trial of an RSV inactivated vaccine, 16 of the 20 infants in the test group had severe illness and required hospitalization, with a hospitalization rate of up to 80%, and two infants died.
[0009] mRNA vaccines introduce mRNA encoding viral antigens into the body and express them in the body to produce antigens, which then stimulates the body to produce an immune response. Since mRNA only exists in the cytoplasm and will not be integrated into the host genome and can be naturally degraded in the body, it is safer. mRNA vaccines themselves can be used as adjuvants to induce the body to produce natural immune effects, and mRNA vaccines can induce strong humoral immunity and cellular immunity, generally with stronger immune effects than traditional inactivated vaccines and subunit protein vaccines. mRNA vaccines do not need to be used in combination with other vaccine adjuvants, so they can reduce adverse reactions caused by other substances. Compared with traditional vaccines, the production process of mRNA vaccines is relatively simple, the research and development cycle is short, and it has the technical advantage of rapid response to the research and development of vaccines for emerging infectious diseases. mRNA vaccines have been successful in the development of new coronavirus vaccines, and the safety and effectiveness of mRNA vaccine technology have been proven through large-scale population vaccination.
[0010] Neutralizing antibodies caused by RSV infection are mainly directed against the F protein. RSV F protein is a type I fusion glycoprotein that is relatively conserved among RSV types and is an ideal vaccine antigen target protein. The F protein switches between two conformations: a metastable pre-fusion conformation (pre-F) and a stable post-fusion conformation (post-F). Although the antigenic epitopes targeted by neutralizing antibodies exist on both conformations of the F protein, the characteristics of the natural immune response of humans to RSV infection indicate that most RSV neutralizing antibody epitopes are located in the pre-fusion conformation of the F protein. Due to the instability of the pre-fusion conformation of the F protein, vaccines based on RSV inactivated vaccines or F protein subunit vaccines directly extracted from RSV have all ended in failure.
[0011] Based on the above problems, in order to further reduce the risk of respiratory syncytial virus in people with weakened immunity (including children and the elderly), it is urgent to provide a new type of mRNA vaccine for preventing RSV, which has good stability and can significantly enhance the humoral immune effect after vaccination. Summary of the invention
[0012] The present invention provides an mRNA vaccine encoding RSV F protein, especially the pre-fusion conformation of F protein pre-F. The wild protein sequence of RSV A2 subtype is shown in SEQ ID NO: 1 (GenBank ID: 138251). On the basis of this wild type, it contains three naturally occurring mutations, P102A, I379V and M447V (SEQ ID NO: 210). The sequences after the mutations of these three amino acid residues are conserved in other RSV A strains. Taking into account the differences in the F protein sequences of the current mainstream strains, candidate mutant antigen sequences are designed on this basis.
[0013] RSV virus includes subtype A and B, and the amino acid sequence of its F protein is about 90% identical. For the sequence of F0 precursor polypeptide of A subtype, for example A2 strain (GenBank GI: 138251; Swiss Prot P03420), and the sequence of F0 precursor polypeptide of B subtype, for example, 18537 strain (GenBank GI: 138250; Swiss Prot P13843), both are sequences of 574 amino acids, and the signal peptide sequences of both have also been reported as amino acids 1-25 (GenBank and UniProt). In the two sequences, due to the high homology of the F protein sequence of RSV virus type A and type B, the RSV pre-FmRNA designed by the present invention and the vaccine prepared therefrom are effective for preventing RSV virus type A and type B infection.
[0014] As described herein, using the three-dimensional structure of pre-F as a guide, a stabilized form of the prefusion F protein ("pre-F" antigen) was engineered and constructed and used in an animal model to generate RSV neutralizing immune responses that were comparable to those of Abrysvo. TM The immune response achieved by the immunogen based on RSV F protein has a significant improvement and provides protection against RSV challenge in animal models. The pre-F antigen can be used as a potential vaccine for RSV and as a diagnostic molecule.
[0015] In some embodiments, the recombinant RSV F protein comprises one or more amino acid substitutions that stabilize the protein in a pre-fusion conformation. For example, it stabilizes the membrane distal portion of the F protein (including the N-terminal region of the F1 polypeptide) in a pre-fusion conformation. In a conformation that specifically binds to one or more pre-fusion conformation antibodies and / or presents an antigenic site such as antigenic site Φ that is present in the pre-fusion but not post-fusion conformation of the RSV F protein.
[0016] In other embodiments, the recombinant RSV F protein can include one or more modifications (e.g., truncations and amino acid substitutions) to the C-terminus of the F1 polypeptide, which, together with modifications to stabilize the membrane distal region of the F polypeptide, can increase the stabilization of the recombinant F protein in the prefusion conformation.
[0017] This application relates to the following implementation schemes:
[0018] 1. An immunogenic composition comprising ribonucleic acid (RNA) of respiratory syncytial virus (RSV), wherein the RNA encodes a wild-type RSV F protein or a variant thereof;
[0019] The sequence of the wild-type RSV F protein is SEQ ID NO: 1.
[0020] 2. A composition as described in embodiment 1, wherein the RSV F protein variant comprises one or more mutation forms selected from the following: sequence truncation, sequence deletion and site mutation.
[0021] 3. A composition as described in embodiment 2, wherein the sequence truncation includes the lack of a cytoplasmic domain, for example, the sequence truncation is to cut off the 550-574 amino acids at the C-terminus of the RSV F protein, for example, relative to the wild-type F protein, the truncation retains the 1-549 amino acids of the RSV F protein.
[0022] 4. A composition as described in embodiment 2 or 3, wherein the sequence deletion is selected from one or more of the following: deletion of amino acids at positions 104-136 and deletion of amino acids at positions 104-144; optionally, the amino acids deleted in the sequence are replaced by a GSGS short peptide or a GS short peptide.
[0023] 5. A composition as described in any of embodiments 2 to 4, wherein the site mutation includes one or more selected from the following: P102A, I379V and M447V, for example, the site mutation includes P102A and I379V; P102A and M447V; I379V and M447V; P102A, I379V and M447V.
[0024] 6. A composition as described in embodiment 5, wherein the site mutation also includes one or more selected from the following: S46G, S215P, L373R, S213P and N216P, for example, a site mutation selected from the following: S46G, S215P and L373R.
[0025] 7. The composition according to embodiment 5 or 6, wherein the site mutation further comprises one or more selected from the following:
[0026] (i) Q26C, N27C, T29C, E31C, F32C, Q34C, T36C, S41C, Y44C, Y53C, T54C, S55C, T100C, T103C, L138C, G139C, F 140C, L141C, L142C, G145C, S146C, A147C, I148C, A149C, S150C, V152C, A153C, V154C, S155C, N183GC, S1 86C, L188C, S287C, I288C, S290C, I291C, I292C, V300C, L305C, Y306C, S319C, N325C, S330C, T337C, R339 C, Q354C, T369C, M370C, N371C, S377C, N428C, Y458C, K461C, Q462C, K465C, L467C, Y468C, K470C, G471C;
[0027] (ii) T54H, T58L, S190I, S190F, V207L, T219I, V296I;
[0028] (iii) E92D, K465Q, D486S; and
[0029] (iv) V152I, C69Y, D73E, A74V, N88S.
[0030] 8. The composition of embodiment 5 or 6, wherein the site mutation further comprises one or more combinations selected from the following:
[0031] (i) E31C, Q34C, T54C, S55C, T100C, I148C, A149C, V152C, V154C, S155C, L188C, I288C, S290C, R339C, S377C, Y458C, L467C, G471C;
[0032] (ii) S190F, V296I, V207L, T219I, S190I;
[0033] (iii) E92D, K465Q, D486S; and
[0034] (iv) V152I, C69Y, D73E, A74V, N88S.
[0035] 9. The composition of embodiment 5 or 6, wherein the site mutation further comprises one or more combinations selected from the following:
[0036] (i) T54C, S55C, T100C, I148C, A149C, V152C, V154C, S155C, L188C, I288C, S290C, R339C, S377C, Y458C;
[0037] (ii) S190F, V296I, V207L, T219I, S190I;
[0038] (iii) E92D, K465Q, D486S; and
[0039] (iv) V152I, C69Y, D73E, A74V, N88S.
[0040] 10. The composition of embodiment 5 or 6, wherein the site mutation further comprises one or more combinations selected from the following:
[0041] (i) T54C, I148C, A149C, V152C, S155C, I288C, S290C, Y458C;
[0042] (ii) S190F, V296I, V207L;
[0043] (iii) E92D, K465Q, D486S; and
[0044] (iv) V152I, C69Y, D73E, A74V, N88S.
[0045] 11. A composition as described in any one of embodiments 1 to 10, wherein the RSV F protein variant comprises P102A, I379V and M447V mutations, the RSV F protein variant is a truncated protein after amino acids 550-574 are truncated in SEQ ID NO: 1, and amino acids 104-144 are replaced with a GS linker, and the RSV F protein variant further comprises a site mutation combination selected from any one of the following groups:
[0046] .
[0047] 12. A composition as described in any one of embodiments 1 to 10, wherein the RSV F protein variant comprises P102A, I379V and M447V mutations, the RSV F protein variant is a truncated protein after amino acids 550-574 in SEQ ID NO: 1 are truncated, and amino acids 104-144 are replaced with a GS linker, and the RSV F protein variant further comprises a site mutation combination selected from any one of the following groups:
[0048] .
[0049] 13. A composition as described in any one of embodiments 1 to 10, wherein the RSV F protein variant comprises P102A, I379V and M447V mutations, the RSV F protein variant is a truncated protein after amino acids 550-574 of SEQ ID NO: 1 are truncated, and amino acids 104-144 are replaced with a GS linker, and the RSV F protein variant further comprises a combination of mutations selected from any one of the following groups:
[0050] .
[0051] 14. A composition as described in any one of embodiments 1 to 13, wherein the variant of the RSV F protein comprises SEQ ID NO: 204 (YK-RSV-061), SEQ ID NO: 12 (YK-RSV-003), SEQ ID NO: 208 (YK-RSV-062), SEQ ID NO: 176 (YK-RSV-054), SEQ ID NO: 116 (YK-RSV-039), SEQ ID NO: 136 (YK-RSV-044), SEQ ID NO: 40 (YK-RSV-012), SEQ ID NO: 52 (YK-RSV-015), SEQ ID NO: 4 (YK-RSV-001), SEQ ID NO: 104 (YK-RSV-036), SEQ ID NO: 200 (YK-RSV-060), SEQ ID NO: The amino acid sequence of SEQ ID NO: 36 (YK-RSV-011) or SEQ ID NO: 80 (YK-RSV-030) has at least 80%, 85%, 90%, 95% or at least 98% or 100% identity.
[0052] 15. A composition as described in embodiment 14, wherein the variant of the RSV F protein comprises SEQ ID NO: 204 (YK-RSV-061), SEQ ID NO: 12 (YK-RSV-003), SEQ ID NO: 208 (YK-RSV-062), SEQ ID NO: 176 (YK-RSV-054), SEQ ID NO: 116 (YK-RSV-039), SEQ ID NO: 136 (YK-RSV-044), SEQ ID NO: 40 (YK-RSV-012), SEQ ID NO: 52 (YK-RSV-015), SEQ ID NO: 4 (YK-RSV-001), SEQ ID NO: 104 (YK-RSV-036) or SEQ ID NO: The sequence of 200 (YK-RSV-060) has an amino acid sequence that is at least 80%, 85%, 90%, 95%, or at least 98% or 100% identical.
[0053] 16. A composition as described in embodiment 15, wherein the variant of the RSV F protein comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or at least 98% or 100% identical to the sequence of SEQ ID NO: 204 (YK-RSV-061), SEQ ID NO: 12 (YK-RSV-003), SEQ ID NO: 208 (YK-RSV-062), SEQ ID NO: 176 (YK-RSV-054) or SEQ ID NO: 116 (YK-RSV-039).
[0054] 17. A composition as described in any of embodiments 1 to 16, wherein the open reading frame (ORF) encoding the RSV F protein or a variant thereof comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, or at least 98%, or 100% identical to SEQ ID NO: 203, SEQ ID NO: 11, SEQ ID NO: 207, SEQ ID NO: 175, SEQ ID NO: 115, SEQ ID NO: 135, SEQ ID NO: 39, SEQ ID NO: 51, SEQ ID NO: 3, SEQ ID NO: 103, SEQ ID NO: 199, SEQ ID NO: 35, or SEQ ID NO: 79.
[0055] 18. A composition as described in embodiment 17, wherein the ORF comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, or at least 98% or 100% identical to SEQ ID NO: 203, SEQ ID NO: 11, SEQ ID NO: 207, SEQ ID NO: 175, SEQ ID NO: 115, SEQ ID NO: 135, SEQ ID NO: 39, SEQ ID NO: 51, SEQ ID NO: 3, SEQ ID NO: 103, or SEQ ID NO: 199.
[0056] 19. A composition as described in embodiment 18, wherein the ORF comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95% or at least 98% or 100% identical to SEQ ID NO: 203, SEQ ID NO: 11, SEQ ID NO: 207, SEQ ID NO: 175 or SEQ ID NO: 115.
[0057] 20. The composition of any one of embodiments 1 to 19, wherein the RNA of RSV further comprises a 5′ untranslated region (UTR).
[0058] 21. The composition of embodiment 20, wherein the sequence of the 5′UTR is: SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220 or SEQ ID NO:221.
[0059] 22. The composition of embodiment 21, wherein the sequence of the 5′UTR is SEQ ID NO: 217.
[0060] 23. The composition of any one of embodiments 1 to 22, wherein the RNA of RSV further comprises a 3′ untranslated region (UTR).
[0061] 24. The composition of embodiment 23, wherein the sequence of the 3′UTR is: SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224 or SEQ ID NO:225.
[0062] 25. The composition of embodiment 24, wherein the sequence of the 3′UTR is SEQ ID NO:222.
[0063] 26. A composition as described in any one of embodiments 1 to 25, wherein the RNA of the RSV further comprises a poly (A) tail.
[0064] 27. A composition as described in Embodiment 26, wherein the length of the Ploy(A) tail is 50 to 150 nucleotides.
[0065] 28. A composition as described in any one of embodiments 1 to 27, wherein the RSV RNA further comprises a 5′-terminal cap structure.
[0066] 29. The composition as described in Embodiment 28, wherein the 5′ end cap structure is: 7mG(5′)ppp(5′)NlmpNp.
[0067] 30. The composition of any one of embodiments 1 to 29, wherein the sequence of the open reading frame (ORF) encoding the RSV F protein or variant thereof in the RSV RNA is codon-optimized.
[0068] 31. A composition as described in embodiment 30, wherein the sequence of the ORF contains at least one base modification.
[0069] 32. A composition as described in embodiment 31, wherein the base modification includes any one or more selected from the following: pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyluridine.
[0070] 33. A composition as described in embodiment 32, wherein the base modification includes replacing uracil with pseudouridine and / or N1-methylpseudouridine.
[0071] 34. A composition as described in Embodiment 31, wherein the base modification is 1~100% base modification, for example, 100% base modification.
[0072] 35. A composition as described in any of embodiments 1 to 34, wherein the sequence of the RNA of the RSV is at least 80%, 85%, 90%, 95% or at least 98% or 100% identical to SEQ ID NO: 205, SEQ ID NO: 13, SEQ ID NO: 209, SEQ ID NO: 177, SEQ ID NO: 117, SEQ ID NO: 137, SEQ ID NO: 41, SEQ ID NO: 53, SEQ ID NO: 5, SEQ ID NO: 105, SEQ ID NO: 201, SEQ ID NO: 37 or SEQ ID NO: 81.
[0073] 36. A composition as described in embodiment 35, wherein the sequence of the RNA of the RSV is at least 80%, 85%, 90%, 95% or at least 98% or 100% identical to SEQ ID NO: 205, SEQ ID NO: 13, SEQ ID NO: 209, SEQ ID NO: 177, SEQ ID NO: 117, SEQ ID NO: 137, SEQ ID NO: 41, SEQ ID NO: 53, SEQ ID NO: 5, SEQ ID NO: 105 or SEQ ID NO: 201.
[0074] 37. A composition as described in embodiment 36, wherein the sequence of the RNA of the RSV is at least 80%, 85%, 90%, 95% or at least 98% or 100% identical to SEQ ID NO: 205, SEQ ID NO: 13, SEQ ID NO: 209, SEQ ID NO: 177 or SEQ ID NO: 117.
[0075] 38. A composition as described in any one of embodiments 1 to 37, wherein the RNA of RSV is mRNA.
[0076] 39. A composition as described in any one of embodiments 1 to 38, wherein the sequence encoding the RSV F protein or its variant is at least 80%, 85%, 90%, 95%, or at least 98% or 100% identical to SEQ ID NO: 202, SEQ ID NO: 10, SEQ ID NO: 206, SEQ ID NO: 174, SEQ ID NO: 114, SEQ ID NO: 134, SEQ ID NO: 38, SEQ ID NO: 50, SEQ ID NO: 2, SEQ ID NO: 102, SEQ ID NO: 198, SEQ ID NO: 34, or SEQ ID NO: 78.
[0077] 40. A composition as described in embodiment 39, wherein the sequence encoding the RSV F protein or its variant is at least 80%, 85%, 90%, 95%, or at least 98% or 100% identical to SEQ ID NO: 202, SEQ ID NO: 10, SEQ ID NO: 206, SEQ ID NO: 174, SEQ ID NO: 114, SEQ ID NO: 134, SEQ ID NO: 38, SEQ ID NO: 50, SEQ ID NO: 2, SEQ ID NO: 102 or SEQ ID NO: 198.
[0078] 41. A composition as described in embodiment 40, wherein the sequence encoding the RSV F protein or its variant is at least 80%, 85%, 90%, 95%, or at least 98% or 100% identical to SEQ ID NO: 202, SEQ ID NO: 10, SEQ ID NO: 206, SEQ ID NO: 174 or SEQ ID NO: 114.
[0079] 42. A method for preparing a composition as described in any one of embodiments 1 to 41, comprising:
[0080] Providing a template for transcribing the RSV RNA;
[0081] The template is used for transcription under conditions suitable for transcribing the RNA.
[0082] 43. The method according to embodiment 42 further includes a purification step selected from the following: lithium chloride precipitation, affinity chromatography, ultrafiltration exchange, cellulose chromatography.
[0083] 44. The composition of any one of embodiments 1 to 41, which is a vaccine and further comprises a pharmaceutically acceptable carrier.
[0084] 45. A composition as described in embodiment 44, wherein the pharmaceutically acceptable carrier comprises a lipid mixture, such as a lipid nanoparticle (LNP).
[0085] 46. A composition as described in embodiment 44 or 45, wherein the vaccine is an mRNA vaccine.
[0086] 47. A composition as described in embodiment 45, wherein the lipid nanoparticles, for example, comprise cationic lipids, neutral lipids, structural lipids and polymer-conjugated lipids.
[0087] 48. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula I, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G 1 C 1~6 Alkylene; G 2 C 2~8 Alkylene; G 3 C 1~3 Alkylene; L 1 C 6~15 Straight chain alkyl; L 2 C 12~25 Branched chain alkyl;
[0088] For example, YK-009 of formula II:
[0089] .
[0090] 49. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula II structure, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G 1 C 2~8 Alkylene; G 2 C 2~8 Alkylene; L 1 is -C(O)O- or -OC(O)-; L 2is -C(O)O- or -OC(O)-; R 1 C 6~25 Straight or branched alkyl; R 2 C 6~25 Straight or branched alkyl; G 3 HO(CH 2 ) 2 - or HO(CH 2 ) 3 -;G 4 HO(CH 2 ) 2 - or HO(CH 2 ) 3 -; L is (CH 2 ) 2 -or-(CH 2 ) 3 -or-(CH 2 ) 4 -;
[0091] For example, YK-401 of formula II-I or YK-402 of formula II-II:
[0092] .
[0093] 50. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula III, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G 1 C 1~6 Alkylene; G 2 C 2~8 Alkylene; R 1 C 6~20 Straight or branched alkyl; R 2 C 12~25 Branched alkyl; G 3 HO(CH 2 ) 2 N(CH 3 )(CH 2 ) 2 -,HO(CH 2 ) 2 N(CH 2 CH 3 )(CH 2 ) 2 -,(HO(CH 2 ) 2 ) 2 N(CH 2 ) 2 -, CH 3 O(CH 2 )2 N(CH 3 )(CH 2 ) 2 -,(CH 3 ) 2 N(CH 2 ) 3 SC(O)O(CH 2 ) 2 -,(CH 3 ) 2 N(CH 2 ) 3 SC(O)-,CH 3 NH(CH 2 ) 2 N(CH 3 )(CH 2 ) 2 - or CH 3 CH 2 NH(CH 2 ) 2 -;
[0094] For example, YK-201 of formula III-I or YK-202 of formula III-II:
[0095] .
[0096] 51. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula IV, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G 1 C 1~8 Alkylene; G 2 C 2~8 Alkylene; R 1 C 6~25 Straight or branched alkyl; R 2 C 12~25 Straight or branched alkyl; G 3 HO(CH 2 ) 2 N(R 3 )CH 2 CH(OH)CH 2 -, where R 3 -CH 3 or -CH 2 CH 3 or -CH 2 CH 2 OH;
[0097] For example, YK-305 of formula IV-I or YK-310 of formula IV-II:
[0098] .
[0099] 52. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula V, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G 1 and G 2 Each independently is unsubstituted C 6 -C 10 Alkylene; G 3 For unsubstituted C 1 -C 12 Alkylene; R 1 and R 2 Each independently is C 6 -C 24 Alkyl or C 6 -C 24 Alkenyl; R 3 OR 5 、N、-C(=O)OR 4 、-OC(=O)R 4 or -NR 5 C(=O)R 4 ; R 4 C 1 -C 12 A hydrocarbon group; and R 5 H or C 1 -C 6 alkyl;
[0100] For example, ALC0315 of formula VI:
[0101] .
[0102] 53. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula VI, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 Selected from -(CH 2 ) n Q and -(CH 2 ) n CHQR; Q is selected from the group consisting of: -OR, -OH, -O(CH 2 ) n N(R) 2 、-OC(O)R、-CX 3 , -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O) 2 R, -N(H)S(O) 2 R, -N(R)C(O)N(R)2 、-N(H)C(O)N(R) 2 , -N(H)C(O)N(H)(R), -N(R)C(S)N(R) 2 、-N(H)C(S)N(R) 2 , -N(H)C(S)N(H)(R), -N(R)S(O) 2 R 8 and heterocyclic ring; n is 1, 2 or 3; wherein R is hydrogen, C 1~3 Alkyl, C 2~3 Alkenyl or (CH 2 ) q OR * , where q is 1, 2 or 3, R * C 1~12 Alkyl or C 2~12 alkenyl; X is fluorine, chlorine, bromine or iodine; R 8 C 3~6 Cycloalkyl or heterocyclic;
[0103] For example, SM102 of formula VI-I
[0104] .
[0105] 54. A composition as described in embodiment 47, wherein the cationic lipid is a compound of formula VII, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof:
[0106] .
[0107] 55. A composition as described in embodiment 47 above, wherein the cationic lipids include the following compounds: YK-009, YK-401, YK-305, ALC0315, SM102, DLIN-MC3
[0108] .
[0109] 56. A composition as described in any one of embodiments 47 to 55, wherein the molar ratio of the cationic lipid to the neutral lipid is (1 to 10):1.
[0110] 57. A composition as described in any one of embodiments 47 to 55, wherein the molar ratio of the cationic lipid to the structural lipid is (1 to 5):1.
[0111] 58. A composition as described in any one of embodiments 47 to 55, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid and the polymer conjugated lipid is (25-75): (5-25): (15-65): (0.5-10).
[0112] 59. A composition as described in embodiment 58, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid and the polymer conjugated lipid is (35~49):(7.5~15):(35~55):(1~5), for example, 49:10:39.5:1.5 or 45:10:43.5:1.5.
[0113] 60. A composition as described in any one of embodiments 47 to 59, wherein the neutral lipid is selected from one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol and its derivatives.
[0114] 61. A composition as described in any of embodiments 47 to 60, wherein the neutral lipid is selected from one or more of the following: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diondecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0Diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (MEPE), 1,2-di- ... ,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoyl Phosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine and lysophosphatidylethanolamine (LPE).
[0115] 62. The composition of any one of embodiments 47 to 61, wherein the neutral lipid is DOPE and / or DSPC.
[0116] 63. A composition as described in any one of embodiments 47 to 62, wherein the structured lipid is selected from one or more of the following: cholesterol, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid, α-tocopherol, corticosteroids.
[0117] 64. A composition as described in embodiment 63, wherein the structured lipid is cholesterol.
[0118] 65. A composition as described in any of embodiments 47 to 64, wherein the polymer-conjugated lipid is selected from one or more of the following: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol.
[0119] 66. A composition as described in embodiment 65 above, wherein the polymer conjugated lipid is selected from one or more of the following: distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG2000) and methoxypolyethylene glycol ditetradecanoyl acetamide (ALC-0159).
[0120] 67. A composition as described in any one of embodiments 44 to 66, wherein the effective dose of RSV RNA is 25 μg~200 μg; preferably 50 μg~100 μg.
[0121] 68. The composition of any one of embodiments 44 to 67, wherein the vaccine is in the form of an injectable dosage form.
[0122] 69. A method for preparing a composition as described in any one of embodiments 44 to 68, comprising: mixing the RSV RNA with the pharmaceutically acceptable carrier, for example to encapsulate at least a portion of the RNA inside a lipid nanoparticle.
[0123] 70. Use of a composition according to any one of embodiments 1 to 41 and 44 to 68 for the preparation of a vaccine for inducing a protective immune response, particularly a humoral immune response, against RSV in a subject, wherein the protective immune response, for example, includes the production of neutralizing antibodies, wherein the subject is, for example, over 40 years old or under 10 years old, for example, over 50 years old, over 55 years old, over 60 years old, over 65 years old, over 70 years old, over 75 years old or over 80 years old, or under 8 years old, under 7 years old, under 6 years old, under 5 years old, under 4 years old, under 3 years old or under 2 years old.
[0124] 71. Use of the composition of any one of embodiments 1 to 41 and 44 to 68 in the preparation of a vaccine for preventing RSV infection.
[0125] The beneficial effects of the present invention are at least one of the following:
[0126] Based on the wild-type RSV F protein, the present application obtains at least 11 RNAs encoding RSV F protein variants through specific variant forms (including sequence truncation, site mutation and / or sequence deletion), thereby providing a new type of mRNA vaccine for preventing RSV, which has high stability and can significantly enhance the humoral immune effect after vaccination. The effect includes at least one of the following:
[0127] Improve the binding rate of the prefusion Φ epitope on RSV F mutants to the corresponding antibody;
[0128] Improve the stability of the prefusion conformation of RSV F mutants after treatment under different temperature, osmotic pressure and pH conditions;
[0129] Improve the binding quantity and binding capacity of antibodies to RSV F mutant pre-fusion conformation-specific antigenic epitopes (Φ epitope, Quaternary epitope and / or V epitope);
[0130] Improve the neutralizing antibody titer produced after RSV F protein immunization;
[0131] Significantly reduced inflammation and viral load in the body (including the lungs and nasal turbinates);
[0132] It can be applied to multiple RSV subtypes at the same time.
[0133] Specifically, the results and technical effects of the present invention are as follows:
[0134] (1) By Western Blot detection, the results showed that obvious protein expression was observed in the following 50 RSV F mutants: YK-RSV-001, YK-RSV-002, YK-RSV-003, YK-RSV-004, YK-RSV-005, YK-RSV-008, YK-RSV-009, YK-RSV-010, YK-RSV-011, YK-RSV-012, YK-RSV-013, YK-RSV-014, YK-RSV-015, YK-RSV-016, YK-RSV-017, YK-RSV-018, YK-RSV-019, YK-RSV-022, YK-RSV-029, YK-RSV-030, YK-RSV-031, YK-RSV-032, YK-RSV-033, YK-RSV-034, YK-RSV-035, YK-RSV-036, YK-RSV-037, YK-RSV-038, YK-RSV-039, YK-RSV-040, YK-RSV-041, YK-RSV-042, YK-RSV-043, YK-RSV-044, YK-RSV-045, YK-RSV-046, YK-RSV-048, YK-RSV-050, YK-RSV-051, YK-RSV-052, YK-RSV-053, YK-RSV-054, YK-RSV-055, YK-RSV-056, YK-RSV-057, YK-RSV-058, YK-RSV-059, YK-RSV-060, YK-RSV-061 and YK-RSV-062.
[0135] (2) By testing the binding rate between the epitopes on RSV F mutants and the corresponding antibodies, the following 42 RSV strains were screened F mutants (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, YK-RSV-06 0. YK-RSV-005, YK-RSV-010, YK-RSV-017, YK-RSV-030, YK-RSV-038, YK-RSV-043, YK-RSV-055, YK-RSV-056, YK-RSV-057, YK-RSV-048, YK-RSV-052, YK- The binding rates of the Φ epitope and II epitope on RSV-013, YK-RSV-002, YK-RSV-009, YK-RSV-050, YK-RSV-032, YK-RSV-019, YK-RSV-040, YK-RSV-046, YK-RSV-008, YK-RSV-059, YK-RSV-034, YK-RSV-004, YK-RSV-058, YK-RSV-016, YK-RSV-029, YK-RSV-035, YK-RSV-037, YK-RSV-011, YK-RSV-045, and YK-RSV-051) with the corresponding antibodies are about 80% or more, and the binding rates are all good.
[0136] (3) Through stability tests after stress treatment under different temperature, osmotic pressure and pH conditions, the following 20 mutants (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, YK-RSV-060, YK-RSV-009, YK-RSV-010, YK-RSV-011, YK-RSV-030, YK-RSV-043, YK-RSV-048, YK-RSV-050, YK-RSV-055, and YK-RSV-057) were screened out. After storage at 100 °C for one week, the stress resistance parameters were all above 0.44, and could be as high as 0.68; after incubation at 50 °C for 60 min, the stress resistance parameters were all above 0.64; after treatment under high osmotic pressure for 60 min, the stress resistance parameters were all above 0.61; after treatment under low osmotic pressure for 60 min, the stress resistance parameters were all above 0.70; after treatment under pH=3.5 and pH=10 for 60 min, the stress resistance parameters were all above 0.56. The stress resistance parameters after treatment under the above different conditions were better than those of the control or equivalent to them.
[0137] (4) The binding levels of different epitopes to the corresponding antibodies were detected by ELISA, and the Φ epitope, Quaternary epitope, and V epitope on the following 15 mutants (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, YK-RSV-060, YK-RSV-011, YK-RSV-030, YK-RSV-048, and YK-RSV-050) were screened out and all of them could bind well to the corresponding antibodies, with a large number of epitope binding and a strong binding ability.
[0138] For example, the binding level of the Φ epitope on YK-RSV-061, YK-RSV-003, and YK-RSV-062 to the RSV pre-F antibody (3C12) was 1.83 to 2.00 times that of the control PC-RSV-064; the binding level of the Quaternary epitope to the RSV pre-F antibody (7H11) was 2.01 to 2.12 times that of the control PC-RSV-064.
[0139] The binding level of the Φ epitope on YK-RSV-054 to RSV pre-F antibody (3C12) was 2.52 times that of the control PC-RSV-064; the binding level of the Quaternary epitope to RSV pre-F antibody (7H11) was 1.82 times that of the control PC-RSV-064; the binding level of the V epitope to RSV F antibody (7E11) was 3.30 times that of the control PC-RSV-064; the binding level of the II epitope to RSV F antibody (11A9) was 1.79 times that of the control PC-RSV-064; and the binding level of the III epitope to RSV F antibody (4B9) was 2.27 times that of the control PC-RSV-064.
[0140] (5) The BLI method was used to analyze the affinity between the target protein and different antibodies. The test results showed that the Φ epitope and Quaternary epitope on 13 mutants (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, YK-RSV-060, YK-RSV-011, and YK-RSV-030) had the strongest affinity for binding to the corresponding antibodies.
[0141] The affinity constant K of the Φ epitope on the mutant binding to RSV pre-F antibody (3C12) D The K of the control group was 3.26E-12~7.79E-11 M, which was significantly lower than that of the control group. D Value (K D About E-10 M, a difference of 1 to 2 orders of magnitude), indicating that the affinity between antigen and antibody is strong.
[0142] The affinity constant K of the quadrenary epitope on the mutant binding to RSV pre-F antibody (7H11) D The range was 3.05E-12~6.13E-10 M, except for YK-RSV-044, YK-RSV-060 and YK-RSV-030 and the control K D The K D The values were significantly lower than those of the control (1 to 2 orders of magnitude), indicating that the affinity between the antigen and the antibody was strong. (6)
[0144] Mouse: Binding Antibody
[0145] The ELISA method was used to detect the pre-fusion and post-fusion F protein-specific IgG titers in the serum of mice on the 35th day after immunization. The test results screened out that the pre-F IgG antibody titers of 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060) were Abrysvo TM The positive control was 2.52 ~ 5.31 times, and the post-F IgG antibody titer was Abrysvo TM 1.13 ~5.21 times of the positive control.
[0146] In all tested substances, the pre-F / post-F ratios were higher than 1, indicating that the pre-fusion conformation F protein produced higher IgG titers than the post-fusion conformation F protein.
[0147] Mouse: Neutralizing Antibodies
[0148] 1) RSV type A virus: The neutralizing antibody titer IC of 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060) was screened by using a spot reduction-based microneutralization test method to detect the neutralizing antibody titer IC of 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060) on the 35th day after mouse immunization. 50 For Abrysvo TM 3.72 ~12.67 times of the positive control, IC 90 For Abrysvo TM The results were 2.34~14.41 times of the positive control, which were both better than the positive control.
[0149] 2) RSV B virus: Neutralizing antibody titer IC of 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, YK-RSV-060) 50 For Abrysvo TM 2.85 ~10.63 times of the positive control, IC 90 For Abrysvo TMThe neutralizing antibody titers were 2.88 to 14.23 times that of the positive control and were significantly higher than those of the positive control. (7)
[0151] Cotton rat: binding antibodies
[0152] ELISA was used to detect the pre-fusion and post-fusion F protein-specific IgG titers in the serum of cotton rats on days 42 and 48 after immunization. 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060):
[0153] The pre-F IgG antibody titer on day 42 was Abrysvo TM The positive control was 3.05~13.10 times, and the post-F IgG antibody titer was Abrysvo TM The pre-F / post-F ratios of all tested substances ranged from 1.39 to 3.95, indicating that the IgG antibody titer produced by the pre-fusion F protein was significantly higher than that of the post-fusion F protein.
[0154] The pre-F IgG antibody titer on day 48 was Abrysvo TM The positive control was 4.44~12.35 times, and the post-F IgG antibody titer was Abrysvo TM The pre-F / post-F ratios of all tested substances ranged from 1.78 to 4.29 times, indicating that the IgG antibody titer produced by the pre-fusion F protein was still significantly higher than that of the post-fusion F protein after immunization on the 48th day.
[0155] Cotton rat: neutralizing antibodies
[0156] By testing the neutralizing antibody titers against RSV A2 virus in cotton rat serum, the test results showed that 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, YK-RSV-060):
[0157] 1) On the 42nd day after immunization, neutralizing antibody titer IC against RSV A2 virus 50For Abrysvo TM 2.10 ~14.30 times of positive control, IC 90 For Abrysvo TM The levels of leukemia / aspartate amino acids in the samples were 2.26 to 22.33 times of the positive control, which were significantly higher than those in the positive control.
[0158] IC of neutralizing antibodies produced against RSV B virus 50 For Abrysvo TM 2.16~14.63 times of the positive control, IC 90 For Abrysvo TM The levels of leukemia / aspartate amino acids in the samples were 2.49 to 17.26 times that of the positive control, which were significantly higher than those of the positive control.
[0159] 2) IC titer of neutralizing antibodies against RSV A2 virus on day 48 after immunization 50 For Abrysvo TM 1.70 ~7.57 times of positive control, IC 90 For Abrysvo TM The levels of leukocytes in the samples were 1.46~11.56 times higher than those in the positive control.
[0160] (8) The results of cotton rat lung pathological sections showed that for 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060), the scores of peribronchiolar infiltration were between 0.33 and 0.83, indicating mild inflammatory infiltration. The interstitial infiltration scores of all test substances were better than those of the positive control Abrysvo. TM , the score was 0.67~1.17, which was mild inflammatory infiltration. The overall inflammatory response score of all test substances was low, and the total pathological score was between 1.00 and 2.00, which was lower than that of the control LNP. Among them, the scores of perivascular infiltration and alveolar infiltration of the control and test substances were both 0, and there were no visible lesions in the tissue.
[0161] (9) Results of viral load in the lungs and nasal turbinates of cotton rats showed that the viral load in the lungs of the 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060) after immunization was 1.61 to 2.08, which was lower than that of the positive control Abrysvo. TM; The viral load of nasal turbinates was 0.62~1.51, which was only the positive control Abrysvo TM The viral load was significantly reduced, indicating that the test substance had a good antiviral effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0162] Figure 1 : Antigen expression of YK-RSV-001~YK- RSV-062;
[0163] Figure 2 (A) and (B) are the RSV A2 pre-F binding antibody titers in mouse serum on day 35, respectively;
[0164] Figure 3 (A) and (B) are the RSV A2 post-F binding antibody titers in mouse serum on day 35, respectively;
[0165] Figure 4 (A) and (B) are the IC values of RSV A2 neutralizing antibodies in mouse serum on day 35. 50 ;
[0166] Figure 5 (A) and (B) are the IC values of RSV A2 neutralizing antibodies in mouse serum on day 35. 90 ;
[0167] Figure 6 (A) and (B) are the IC values of RSV B neutralizing antibodies in mouse serum on day 35. 50 ;
[0168] Figure 7 (A) and (B) are the IC values of RSV B neutralizing antibodies in mouse serum on day 35. 90 ;
[0169] Figure 8 (A) and (B) are the RSV A2 pre-F binding antibody titers in cotton rat serum on day 42, respectively;
[0170] Fig. 9 (A) and (B) are the RSV A2 post-F binding antibody titers in cotton rat serum on day 42, respectively;
[0171] Fig.10 (A) and (B) are the RSV A2 pre-F binding antibody titers in cotton rat serum on day 48, respectively;
[0172] Fig.11 (A) and (B) are the RSV A2 post-F binding antibody titers in cotton rat serum on day 48, respectively;
[0173] Fig.12 (A) and (B) are the IC values of RSV A2 neutralizing antibodies in cotton rat serum on day 42. 50 ;
[0174] Fig.13 (A) and (B) are the IC values of RSV A2 neutralizing antibodies in cotton rat serum on day 42. 90 ;
[0175] Fig.14 (A) and (B) are the IC values of RSV B neutralizing antibodies in cotton rat serum on day 42. 50 ;
[0176] Fig.15 (A) and (B) are the IC values of RSV B neutralizing antibodies in cotton rat serum on day 42. 90 ;
[0177] Fig.16 (A) and (B) are the IC values of RSV A2 neutralizing antibodies in cotton rat serum on day 48. 50 ;
[0178] Fig.17 (A) and (B) are the IC values of RSV A2 neutralizing antibodies in cotton rat serum on day 48. 90 ;
[0179] Fig.18 : Shows the results of pathological sections of the lungs of cotton rats treated with the test substance of the present invention. DETAILED DESCRIPTION
[0180] The present invention is further described below by way of examples. It should be understood that the examples of the present invention are provided only for illustrating the present invention, rather than limiting the present invention, and simple improvements to the present invention based on the technical solution of the present invention all fall within the protection scope of the present invention.
[0181] As used herein, amino acid residues are abbreviated as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).
[0182] As used herein, the following terms have the meanings indicated below.
[0183] vaccine
[0184] Refers to an immunogen that is capable of eliciting a prophylactic or therapeutic immune response in an individual, which may be in the form of a pharmaceutical composition. Typically, vaccines induce an antigen-specific immune response against an antigen of a pathogen, such as a viral pathogen.
[0185] Nucleic Acids
[0186] Nucleic acid is a polymer comprising nucleotides (nucleotide monomers). Therefore, nucleic acid is also referred to as polynucleotide. Nucleic acid can be or can include, for example, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA, including LNA with β-D-ribose configuration, α-LNA with α-L-ribose configuration (diastereomers of LNA), 2 '-amino-LNA with 2 '-amino functionalization and 2 '-amino-α-LNA with 2 '-amino functionalization), ethylene nucleic acid (ENA), cyclohexenyl nucleic acid (CeNA) and / or its chimera and / or its combination.
[0187] Messenger RNA (mRNA) is any RNA that encodes (at least one) protein (a naturally occurring, non-naturally occurring or modified amino acid polymer) and can be translated in vitro, in vivo, in situ or ex vivo to produce an encoded protein. It will be understood by those skilled in the art that, unless otherwise indicated, the nucleic acid sequences set forth in this application may list "T" in representative DNA sequences, but in the case where the sequence represents RNA (e.g., mRNA), "T" will replace "U". Therefore, any DNA disclosed and identified herein by a specific sequence identification number also discloses a corresponding RNA (e.g., mRNA) sequence complementary to the DNA, wherein each "T" of the DNA sequence is replaced by a "U".
[0188] An open reading frame (ORF) is a continuous stretch of DNA or RNA that begins with a start codon (e.g., methionine (ATG or AUG)) and ends with a stop codon (e.g., TAA, TAG, or TGA, or UAA, UAG, or UGA). An ORF typically encodes a protein. It should be understood that the sequences disclosed herein may also contain additional elements, e.g., 5' and 3' UTRs, but unlike ORFs, these elements are not necessarily present in the RNA polynucleotides disclosed herein.
[0189] The compositions disclosed herein comprise RNA having an open reading frame (ORF) encoding a respiratory syncytial virus antigen. In some embodiments, the RNA is a messenger RNA (mRNA). In some embodiments, the RNA (e.g., mRNA) further comprises a 5′UTR, a 3′UTR, a poly (A) tail, and / or a 5′ cap analog (or 5′ cap end cap structure).
[0190] It should also be understood that the mRNA vaccines disclosed herein may include any 5' untranslated region (UTR) and / or any 3' UTR. Exemplary UTR sequences are provided in the sequence table; however, other UTR sequences may be used or replaced with any UTR sequence described herein. UTRs may also be omitted from the RNA polynucleotides provided herein.
[0191] antigen
[0192] An antigen is a protein that is capable of inducing an immune response (e.g., causing the immune system to produce antibodies against the antigen). As used herein, the term "antigen" encompasses immunogenic proteins and immunogenic fragments that induce (or are capable of inducing) an immune response to (at least one) respiratory syncytial virus, e.g., RSV A2 (138251), unless otherwise indicated. It should be understood that the term "protein" encompasses peptides and the term "antigen" encompasses antigenic fragments.
[0193] Exemplary sequences of respiratory syncytial virus antigens and RNA encoding the respiratory syncytial virus antigens of the compositions of the present disclosure are provided in the Sequence Listing.
[0194] Epitope
[0195] Also known as antigenic determinant, it refers to a specific area on an antigen molecule that can be recognized by a specific antibody. There may be one or more epitopes on an antigen molecule. Antigenic epitopes can be recognized by the surface receptors of B cells (B-cell receptor, BCR), triggering subsequent antibody synthesis and secretion and mediating humoral immune responses. The pre-fusion pre-F conformation has six major antigenic sites / epitopes (including Φ, I, II, III, IV and V epitopes). Through the crystal structure analysis of RSV F protein, it was found that the AM14 antibody specifically recognizes a Quaternary epitope spanning two protomers, including a region that undergoes extensive conformational changes in the transition of F protein from pre-fusion to post-fusion. These epitopes are highly antigenic but relatively unstable; while the post-F conformation after fusion has only four antigenic sites / epitopes (including I, II, III and IV epitopes), which is relatively stable but not highly antigenic. Compared to epitopes I, II, III and IV, which exist in both pre-fusion and post-fusion conformations, epitopes Φ and V exist only in the pre-F conformation, and studies have confirmed that they are sites sensitive to neutralizing antibodies and can induce higher neutralizing antibody responses. The antibody recognition epitopes in the present disclosure are as follows:
[0196] ① The RSV pre-F antibody (3C12) that recognizes the Φ epitope only specifically binds to the F protein in the pre-fusion conformation.
[0197] ②RSV pre-F antibody (7H11) recognizes the Quaternary epitope (spanning epitopes IV and V) and specifically binds to the F protein in the pre-fusion conformation.
[0198] ③ RSV F antibody (11A9) that recognizes epitope II can simultaneously recognize the pre-fusion and post-fusion conformations of the F protein.
[0199] ④ RSV F antibody (4B9) that recognizes epitope III prefers to recognize the pre-fusion conformation and has weak binding activity with the post-fusion conformation.
[0200] ⑤ RSV pre-F antibody (7E11) recognizes the V epitope and specifically binds to the F protein in the pre-fusion conformation.
[0201] Studies have shown that the ability to specifically bind to the Φ epitope of the prefusion antigen is closely related to the effectiveness of the new vaccine in preventing RSV infection. The Φ and II epitopes account for ~35% and <10% of the neutralizing activity, respectively. The neutralizing activity of RSV in human serum mainly comes from prefusion-specific antibodies. Therefore, the use of prefusion antigens that retain the Φ epitope will help induce or enhance neutralizing activity through vaccination.
[0202] The antigenic epitopes of RSV F protein change before and after fusion, among which the Φ epitope is only retained in the pre-fusion conformation, and the II epitope is retained in both the pre-fusion and post-fusion conformations. Antibodies specific for the Φ epitope of the antigen are different from neutralizing antibodies for other known antigenic epitopes on RSV F protein because they can only specifically recognize the pre-F structure. Studies have shown that the ability to specifically bind to the Φ epitope of the pre-fusion antigen and the ability to bind are closely related to the effectiveness of the new vaccine in preventing RSV infection, so it is used as the main indicator for investigation. The Φ epitope is located at the top of the pre-F trimer structure, with little steric hindrance, which is conducive to antibody binding. Therefore, the higher the ability of the antibody to bind to the Φ epitope, the better the prevention effect against RSV.
[0203] Epitope binding analysis using monoclonal antibodies (mAbs) showed that the ability to bind to Φ epitope-specific antibodies (e.g., quantity, binding rate, binding strength, degree of binding, etc.) is correlated with neutralizing activity, while the degree of binding to II epitope is less correlated with neutralization. In addition, the neutralizing activity of RSV in human serum is mainly derived from pre-F specific antibodies, so vaccination utilizes the Φ epitope in the prefusion conformation to enhance neutralizing activity.
[0204] RSV F protein prefusion conformation
[0205] The structural conformation adopted by RSV F protein before triggering the fusion-promoting event, the fusion-promoting event causes RSV F to be converted into a post-fusion conformation and becomes a mature RSV F protein in the secretory system after processing. In some embodiments, whether the antigen encoded by the mutant nucleic acid is stabilized in the pre-fusion conformation can be measured by combining with a specific epitope. The stable pre-fusion RSV F mutant of the present invention is in a pre-fusion conformation, that is, they include (display) at least one epitope, and this at least one epitope is specific to the pre-fusion conformation F protein. The epitope that has a specificity to the pre-fusion conformation F protein is an epitope that does not exist in the post-fusion conformation. The pre-fusion conformation of RSV F protein can contain the same epitopes as those on the RSV F protein expressed on natural RSV virions, and therefore can provide the advantages of neutralizing antibodies for eliciting protection.
[0206] In some embodiments, the stable prefusion RSV F mutant can specifically bind to the RSV pre-F antibody (3C12) that recognizes the Φ epitope and the RSV pre-F antibody (7H11) that recognizes the Quaternary epitope.
[0207] RSV F protein post-fusion conformation
[0208] The structural conformation adopted by the RSV F protein that is not a pre-fusion conformation, and wherein the N-terminal and C-terminal of RSV F protein are close in a stable spiral-spiral. The post-fusion conformation of RSV F protein has been described at the atomic level (see, for example, McLellan et al., J.Virol., 85, 7788, 2011; Swanson et al., Proc.Natl.Acad.Sci.USA, 108, 9619, 2011; and the structural coordinates deposited with PDB accession number 3RRR; The document is each incorporated herein by reference). In the post-fusion conformation, RSV F protein cannot be bound by certain antibodies, such as antibodies that recognize Φ epitopes.
[0209] Variants
[0210] In some embodiments, the compositions of the present disclosure include RNA encoding respiratory syncytial virus antigen variants.Antigenic variants or other polypeptide variants refer to molecules whose amino acid sequences are different from wild-type, natural or reference sequences.Antigenic / polypeptide variants may have substitutions, deletions and / or insertions at certain positions within the amino acid sequence compared to natural or reference sequences.Generally, variants have at least 50% identity with wild-type, natural or reference sequences.In some embodiments, variants have at least 80% or at least 90% identity compared to wild-type, natural or reference sequences, such as at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% or 100% identity.Herein, "mutant" and "variant" are used interchangeably.
[0211] mutation
[0212] The term "mutation" refers to a phenomenon in which an amino acid sequence is changed compared to a wild-type protein sequence. In the present invention, compared to a wild-type RSV F protein, an antigenic mutant has one or more base mutations. After mutation, compared to the amino acid sequence of a reference protein or polypeptide, truncation, amino acid residue deletion or amino acid residue replacement occurs in the amino acid sequence of a protein or polypeptide. In this article, amino acid replacement is performed at a specific position in a protein sequence using the annotation "(amino acid residue in a wild-type protein) (amino acid position) (amino acid residue in an engineered protein)" to represent. For example, Y44C refers to a tyrosine (Y) residue at the 44th position of the amino acid sequence of a reference protein being replaced by a cysteine (C) residue (in a variant of a reference protein). In the case of a variation in the amino acid residues at the same position between different wild-type sequences, the amino acid code before the position number, such as "44C", can be omitted in the annotation.
[0213] Sequence truncation
[0214] Sequence truncation refers to the removal of a continuous portion of the C-terminal amino acid sequence based on the wild-type RSV F protein. For example, in the present invention, sequence truncation is the removal of amino acids 550-574 at the C-terminus of the RSV F protein.
[0215] Sequence missing
[0216] Sequence deletion refers to a partial base deletion at an amino acid site based on the wild-type RSV F protein. For example, in the present invention, the sequence deletion is selected from one or more of the following: amino acid deletion at positions 104-136 and amino acid deletion at positions 104-144.
[0217] Site mutation
[0218] Site mutation refers to a change in one or more amino acid sites based on the wild-type RSV F protein to stabilize the RSV F protein in the pre-fusion conformation. For example, in the present invention, the site mutation is selected from the following: P102A, I379V and M447V, S46G, S215P, L373R, S213P and N216P, Q26C, N27C, T29C, E31C, F32C, Q34C, T36C, S41C, Y44C, Y53C, T54C, S55C, T100C, T103C, L138C, G139C, F140C, L141C, L142C, G145C, S146C, A147C, I148C, A149C, S150C, V152C, A153C, V154C, S155C, N183GC, S186C, L188 C. S287C, I288C, S290C, I291C, I292C, V300C, L305C, Y306C, S319C, N325C , S330C, T337C, R339C, Q354C, T369C, M370C, N371C, S377C, N428C, Y458C, K 461C, Q462C, K465C, L467C, Y468C, K470C, G471C; T54H, T58L, S190I, S190F, V207L, T219I, V296I; E92D, K465Q, D486S; V152I, C69Y, D73E, A74V, N88S. In the above optional site mutations, the amino acid at the same position can undergo one type of site mutation, for example, the above mutations include T54C or T54H, which means that T at position 54 can mutate to C or H, but not both.
[0219] Lacks cytoplasmic domain
[0220] The cytoplasmic domain is composed of polypeptide chain residues 550-574 of the mature RSV F protein. For example, in the present invention, lack of the cytoplasmic domain means that the C-terminal amino acid sequence 550-574 of the antigen mutant is truncated.
[0221] "One or more" / "selected from"
[0222] In this article, "one or more" means selecting one, two or more from the listed objects or elements. Similarly, "selected from" means selecting one, two or more from the list of listed objects or elements, including any combination of the listed objects or elements, such as any combination of two, any combination of three, ..., any combination of multiple, including all combinations of objects. In this sense, "more" may include two or three or more.
[0223] Variant antigens / polypeptides encoded by nucleic acids disclosed herein may contain amino acid changes that confer any of a variety of desired properties, for example, to improve their stability or to enhance immunogenicity in animals. Variant antigens / polypeptides may be prepared using conventional mutagenesis techniques and assayed where appropriate to determine whether they have the desired properties. Assays for determining expression levels and immunogenicity are well known in the art, and exemplary such assays are illustrated in the Examples section.
[0224] In some embodiments, the composition comprises an RNA or RNA ORF comprising the nucleotide sequence of any one of the sequences provided herein (see Sequence Listing), or a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, or 100% identical to the nucleotide sequence of any one of the sequences provided herein.
[0225] The term "identity" refers to the relationship between the sequences of two or more polypeptides (e.g., antigens) or polynucleotides (nucleic acids) as determined by comparing sequences. Identity also refers to the degree of sequence relatedness between or among sequences as determined by the number of matches between two or more amino acid residues or nucleic acid residue strings. Identity measures the percentage of identity matches between the smaller of two or more sequences with gap comparisons (if any) processed by a specific mathematical model or computer program (e.g., "algorithm"). The identity of related antigens or nucleic acids can be easily calculated by known methods. "Identity percentage (%)" when applied to polypeptide or polynucleotide sequences is defined as the percentage of residues in a candidate amino acid or nucleic acid sequence that are identical to the residues (amino acid residues or nucleic acid residues) in the amino acid sequence or nucleic acid sequence of the second sequence after aligning the sequences and introducing gaps (if necessary) to achieve the maximum identity percentage. Methods and computer programs for comparison are well known in the art. It should be understood that identity depends on the calculation of identity percentage, but due to gaps and penalties introduced in the calculation, the values of identity may be different. Typically, variants of a particular polynucleotide or polypeptide (e.g., an antigen) have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity with the particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul et al. (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25: 3389-3402). Another commonly used local alignment technique is based on the Smith-Waterman algorithm (Smith, TF and Waterman, MS (1981) "Identification of common molecular subsequences." J. Mol. Biol. 147: 195-197).A general global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm (Needleman, S.B. and Wunsch, CD (1970) "A general method applicable to the search for similarities in the amino acid sequences of two proteins." J. Mol. Biol. 48: 443-453). Recently, a fast optimal global sequence alignment algorithm (FOGSAA) has been developed that is said to produce global alignments of nucleotide and protein sequences faster than other optimal global alignment methods (including the Needleman-Wunsch algorithm).
[0226] Therefore, polynucleotides encoding peptides or polypeptides containing substitutions, insertions and / or additions, deletions and covalent modifications relative to reference sequences, particularly polypeptide (e.g., antigen) sequences disclosed herein are included within the scope of the present disclosure. In some embodiments, sequences of signal sequences, termination sequences, transmembrane domains, joints, etc. (or encoding them) can be replaced with alternative sequences that achieve the same or similar functions. In some embodiments, cavities in the protein core can be filled, for example, by introducing larger amino acids to improve stability. In other embodiments, the embedded hydrogen bond network can be replaced with hydrophobic residues to improve stability. Such sequences can be easily identified by those skilled in the art.
[0227] The RSV F mutants provided by the present disclosure comprise an F1 polypeptide and an F2 polypeptide, wherein both the F1 polypeptide and the F2 polypeptide include multiple introduced amino acid mutations relative to the amino acid sequence of the corresponding native F protein. The introduction of such amino acid mutations in the RSV F mutant imparts beneficial properties to the mutant, such as enhanced immunogenicity, improved stability, or the formation of a specific desired physical form or conformation of the mutant or improved stability.
[0228] Mutant (variant) structures of RSV F protein
[0229] The F glycoprotein of human RSV is first translated from mRNA into a single 574 amino acid polypeptide precursor (F0) containing an N-terminal signal peptide sequence. After translation, the signal peptide is removed by a signal peptidase in the endoplasmic reticulum. F0 is cleaved by cellular proteases (particularly furin) in the trans-Golgi apparatus at two sites (between amino acid residues 109 / 110 and 136 / 137), removing a short glycosylation intervening sequence (also known as the pep27 region, amino acid residues 110-136) and generating two domains or subunits called F1 (C-terminal portion; amino acids 137-574) and F2 (N-terminal portion; amino acids 26-109). F2 is attached to F1, and the F1-F2 heterodimers assemble as homotrimers in the virion.
[0230] Signal peptide
[0231] "Signal peptide" is a short amino acid sequence (e.g., about 18-25 amino acids in length) that is usually required for translocation across the membrane in the secretory pathway, controlling the entry of most proteins into the secretory pathway in eukaryotic and prokaryotic organisms. The signal peptide is often, but not universally, located at the N-terminus of the polypeptide and is often cleaved off by a signal peptidase after the protein passes through the membrane.
[0232] To enhance production, the F2 domain may be preceded by a secretory signal peptide, such as the native F protein signal peptide or a heterologous signal peptide, for enhanced production and secretion in host cells in which the recombinant pre-F antigen is to be expressed.
[0233] F1 polypeptide
[0234] The term "F1 polypeptide" (F1) refers to the polypeptide chain of mature RSV F protein. Native F1 includes the approximate residues 137-574 of the RSV F0 precursor. As used herein, the term encompasses both native F1 polypeptides and F1 polypeptides from native sequences including modifications (e.g., amino acid substitutions, insertions or deletions), such as modifications designed to stabilize F mutants or enhance the immunogenicity of F mutants.
[0235] F1 includes a hydrophobic fusion peptide (FP) and a heptad repeat region A (HRA) at the N-terminus 137-216, and contains a heptad repeat region B (HRB), a transmembrane (TM, amino acid residues 530-550) and a cytoplasmic region (amino acid residues 551-574) at the C-terminus. In the structure of the RSV F protein mutant, it is not strictly necessary to include the entire F1 domain. Typically, at least a subsequence (or fragment) of the F1 domain is selected and designed to maintain a stable conformation containing an immunodominant epitope of the F protein. F1 contains subsequences of epitopes recognized by many neutralizing antibodies, for example, amino acid residues 262-275 are palivizumab recognition epitope subsequences; amino acid residues 423-436 are Centocor's ch101F monoclonal antibody recognition epitope subsequences; amino acid residues 328-355 contain T cell epitopes. Therefore, the F1 domain polypeptide contains at least about amino acids 262-436 of the RSV F protein polypeptide.
[0236] Connectors
[0237] One or two furin recognition sites can be eliminated by deleting or replacing one or more amino acids of the furin recognition site. With this design, the fusogenic peptide is not cut from F2, which prevents the release of the globular head of the pre-fusion conformer and the accessibility to adjacent membranes. It is predicted that the interaction between the fusogenic peptide and the membrane interface is a major problem of the instability of the pre-fusion state. During the fusion process, the interaction between the fusogenic peptide and the target membrane causes the fusogenic peptide to be exposed from the globular head structure, strengthens the instability of the pre-fusion state, and folds into the post-fusion conformer. This conformational change realizes the membrane fusion process. It is predicted that removing one or both of the two furin cleavage sites prevents the accessibility of the film and the N-terminal part of the fusogenic peptide, which stabilizes the pre-fusion state. Optionally, it is also possible to remove or replace the intermediate pep27 peptide with, for example, a linker peptide. In addition, or optionally, it is possible to remove or replace the non-furin cleavage site (for example, the metalloproteinase site of the 112th-113th) close to the fusogenic peptide.
[0238] The present application adopts to replace the intermediate pep27 peptide with a linker peptide. The analysis of the structural model of the RSV F protein in the pre-fusion state suggests that pep27 produces a large unconstrained loop between F1 and F2, which does not contribute to the stabilization of the pre-fusion state and is removed after furin cleaves the native protein. Commonly used protein linkers include flexible linkers, rigid linkers and cleavable linkers, and the linker used in the present application is a flexible linker.
[0239] The linkers used in this application can be used in this context without disrupting the conformation of the pre-F antigen.
[0240] F2 polypeptide
[0241] The term "F2 polypeptide" (F2) refers to the polypeptide chain of mature RSV F protein. Natural F2 includes the approximate residues 26-109 of RSV F0 precursor. As used herein, the term encompasses both natural F2 polypeptides and F2 polypeptides from native sequences including modifications (e.g., amino acid replacements, insertions or deletions), which are, for example, designed to stabilize F mutants or enhance the immunogenicity of F mutants.
[0242] Those skilled in the art will recognize that it is not strictly necessary to include the entire F2 domain. Typically, conformational considerations are important in selecting a subsequence (or fragment) of the F2 domain. Thus, the F2 domain generally includes a portion of the F2 domain that promotes polypeptide assembly and stability.
[0243] Stabilization element
[0244] Naturally occurring eukaryotic mRNA molecules may contain stabilizing elements, including but not limited to untranslated regions (UTRs) at their 5' end (5'UTR) and / or at their 3' end (3'UTR), in addition to other structural features such as a 5'-cap structure or a 3'-poly (A) tail. Both the 5'UTR and the 3'UTR are typically transcribed from genomic DNA and are elements of pre-mature mRNA. Characteristic structural features of mature mRNA (e.g., 5'-cap and 3'-poly (A) tail) are typically added to transcribed (pre-mature) mRNA during mRNA processing.
[0245] In some embodiments, the composition includes an RNA polynucleotide having an open reading frame encoding at least one antigenic polypeptide having at least one modification, at least one 5' terminal cap, and is formulated within a lipid nanoparticle. 5'-capping of the polynucleotide can be accomplished simultaneously during an in vitro transcription reaction using the following chemical RNA cap analogs according to the manufacturer's protocol to produce a 5'-guanosine cap structure.
[0246] 3 '-poly (A) tail, i.e., poly (A) tail, is usually a section of adenine nucleotides added to the 3 'end of the transcribed mRNA, located downstream of the 3'UTR containing multiple consecutive adenosine monophosphates, for example, in the region just downstream (i.e., 3'). In some cases, it may include about 10 to 400 adenine nucleotides. In some embodiments, the length of the 3 '-poly (A) tail may be an essential element for the stability of individual mRNAs. In relevant biological environments (e.g., in cells, in vivo), the poly (A) tail is used to protect mRNA from enzymatic degradation, such as in the cytoplasm, and to help transcription termination, and / or mRNA export and translation from the nucleus.
[0247] Untranslated region (UTR)
[0248] The mRNA of the present disclosure may include one or more regions or parts that serve as or are used as untranslated regions. When the mRNA is designed to encode at least one target antigen, the nucleic acid may include one or more of these untranslated regions (UTRs). The wild-type untranslated region of the nucleic acid is transcribed but not translated. In the mRNA, the 5′UTR starts at the transcription start site and continues to the start codon, but does not include the start codon; while the 3′UTR starts immediately after the stop codon and continues to the transcription termination signal. There is increasing evidence that UTR plays a regulatory role in the stability and translation of nucleic acid molecules. The regulatory features of UTR can be incorporated into the polynucleotides of the present disclosure to particularly enhance the stability of the molecule. Specific features can also be incorporated to ensure the controlled downregulation of transcripts in the case where the transcripts are misdirected to undesirable organ sites.
[0249] 5'UTR refers to the region of mRNA that is immediately upstream (5') of the start codon (the first codon of the mRNA transcript translated by the ribosome) that does not encode a polypeptide. 5'UTR does not encode a protein (is non-coding). Natural 5'UTRs have characteristics that play a role in translation initiation. They carry imprints such as the Kozak sequence, which is generally known to be involved in the process of ribosome initiation of translation of many genes. The Kozak sequence has the consensus CCR (A / G) CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), which is followed by another 'G'. 5'UTRs are also known to form secondary structures that are involved in the binding of elongation factors.
[0250] 3'UTR refers to the region of mRNA that is immediately downstream (3') of the stop codon (the codon that signals the end of translation of an mRNA transcript) that does not encode a polypeptide. 3'UTR does not encode protein (is non-coding). The natural or wild-type 3'UTR is known to have stretches of adenosine and uridine embedded therein.
[0251] One of ordinary skill in the art will appreciate that a heterologous or synthetic 5'UTR can be used with any desired 3'UTR sequence. For example, a heterologous 5'UTR can be used with a synthetic 3'UTR or a heterologous 3'UTR.
[0252] In vitro transcription of RNA
[0253] The cDNA encoding the polynucleotides described herein can be transcribed using an in vitro transcription (IVT) system. In vitro transcription of RNA is known in the art and is described in International Publication WO / 2014 / 152027, which is incorporated herein by reference in its entirety.
[0254] In some embodiments, the RNA transcript is produced in an in vitro transcription reaction using a linearized DNA template to produce the RNA transcript.
[0255] In some embodiments, the in vitro transcription template encodes a 5' untranslated (UTR) region, contains an open reading frame, and encodes a 3'UTR and a poly(A) tail. The specific nucleic acid sequence composition and length of the in vitro transcription template will depend on the mRNA encoded by the template.
[0256] In vitro transcription systems typically contain a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor, and a polymerase.
[0257] The NTPs may be made in-house or from a supplier. The NTPs may be selected from, but not limited to, those described herein, including natural and non-natural (modified) NTPs.
[0258] In some embodiments, the RNA transcript is capped by enzymatic capping.In some embodiments, the RNA comprises a 5' terminal cap.
[0259] Lipid Nanoparticles (LNP)
[0260] In some embodiments, RNA (e.g., mRNA) of the present disclosure is formulated in lipid nanoparticles (LNPs). Lipid nanoparticles typically include ionizable cationic lipids, non-cationic lipids, sterols, and PEG lipid components and target nucleic acid. Lipid nanoparticles of the present disclosure can be produced using components, compositions, and methods generally known in the art.
[0261] Stability of RSV F protein mutants
[0262] In some embodiments, the mutant antigens encoded by the nucleic acids disclosed herein have superior properties to the wild type, such as enhanced stability of the pre-fusion conformation. The assay method for determining the stability of the pre-fusion conformation has been specifically described in this example.
[0263] In some embodiments, the stability of the antigen encoded by the mutant nucleic acid can be measured by measuring thermal stability and low temperature stability. "Thermostability" in this embodiment refers to the mutant still showing at least one pre-fusion specific epitope after being subjected to an increased temperature (i.e., 50°C) for 60 min, for example, the determination in this application is the binding to the Φ epitope. "Low temperature stability" in this embodiment refers to the mutant still showing at least one pre-fusion specific epitope after being stored at 4°C for one week, for example, the determination in this application is the binding to the Φ epitope. Compared with RSV F polypeptides without one or more mutations described above, some pre-fusion RSV F mutants according to the present invention have increased stability when stored at low temperatures or heated.
[0264] In some embodiments, the stability of an antigen encoded by a mutant nucleic acid can be measured by determining stability under hypo-osmotic and hyper-osmotic conditions.
[0265] "Low osmotic pressure stability" refers in this embodiment to the fact that after incubation under 10 mM NaCl low osmotic pressure conditions for 60 min, the mutant still exhibits at least one pre-fusion specific epitope, for example, the binding to the Φ epitope is determined in this application. Compared to RSV F polypeptides without one or more mutations described above, some pre-fusion RSV F mutants according to the present invention have increased stability under low osmotic pressure conditions.
[0266] "High osmotic pressure stability" refers to the stability of the 2 After hatching 60min under the hyperosmotic pressure condition, mutant still shows the specific epitope before at least one fusion, and for example, measuring in the application is the combination with Φ epitope.Compared with the RSV F polypeptide without one or more sudden changes described above, RSV F mutant also has the stability of increase under the hyperosmotic pressure condition before some fusions of the present invention.
[0267] In some embodiments, the stability of an antigen encoded by a mutant nucleic acid can be measured by determining stability under acid and alkaline conditions.
[0268] "Acid and alkaline stability" refers in this example to the RSV F mutants incubated at room temperature for 60 min at pH 3.5 and pH 10, followed by neutralization to pH 7.4, and the mutants still exhibit at least one pre-fusion specific epitope, for example, binding to the Φ epitope determined in this application. Compared to RSV F polypeptides without one or more of the aforementioned mutations, some pre-fusion RSV F mutants according to the present invention have increased stability under acid and alkaline conditions.
[0269] Biofilm Interferometry
[0270] Bio-Layer Interferometry (BLI) is a label-free, real-time monitoring optical detection technology, which is mainly used for the comprehensive quantitative analysis of biomolecular interactions and protein concentration determination. BLI can monitor the entire molecular binding process in real time and calculate the affinity constant (K D ), binding rate constant (K a ), dissociation rate constant (K d ) and other important data.
[0271] In some embodiments, the affinity of RSV F protein mutants and antibodies of different epitopes is determined by BLI. In this example, the affinity with RSV pre-F antibody (3C12) and RSV pre-F antibody (7H11) is mainly detected.
[0272] Vaccine immunogenicity
[0273] The term "immunogenicity" refers to the ability of a substance to cause, elicit, stimulate or induce an immune response to a specific antigen in an animal in the presence or absence of an adjuvant. In the sense of the present invention, an immunogen is a provided artificial nucleic acid, preferably a translation product of RNA, which comprises at least one coding sequence encoding at least one antigenic peptide, protein derived from RSV as defined herein.
[0274] The term "neutralizing antibodies" refers to antibodies that can prevent pathogens from binding to host cell surface receptors during pathogen infection, thereby preventing pathogens from adhering to target cells and invading target cells to replicate and multiply. The level of "neutralizing antibodies" is usually used to directly reflect the effectiveness of vaccines.
[0275] In some embodiments, the ability of an immune composition (e.g., RNA vaccine) to be effective is measured in a murine model. For example, the immune composition can be administered to a murine model, and the induction of neutralizing antibody titers in the murine model is determined. In some embodiments, the antigen-specific immune response is measured as the geometric mean titer (GMT) of neutralizing antibody titers in mouse or cotton rat serum. The geometric mean titer (GMT) is the average antibody titer of a group of subjects calculated by multiplying all values and taking the nth root of the number, where n is the number of subjects with available data.
[0276] Virus challenge studies can also be used to evaluate the efficacy of the vaccines of the present disclosure. For example, the immune composition can be administered to a murine model, the murine model can be challenged with a virus, and the survival and / or immune response (eg, neutralizing antibody response) of the murine model can be determined.
[0277] Heterocycle "heterocycle" and "heterocyclyl" are used interchangeably herein and refer to non-aromatic heterocyclic groups in which one or more of the atoms forming the ring are heteroatoms, such as oxygen, nitrogen, sulfur atoms, etc., including monocyclic, condensed, bridged and spirocyclic rings. Preferably, there are 5 to 7-membered monocyclic or 7 to 10-membered bi- or tricyclic rings, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and / or sulfur. Examples of "heterocyclyl" include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydropyranyl, morpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one and piperazinyl. The heterocyclic group may be substituted or unsubstituted.
[0278] 1.1 Example 1: Design of RSV F antigen mutants
[0279] The present invention mainly refers to the RSV A2 (138251) protein sequence, and performs P102A, I379V and M447V mutations on this basis (the antigen sequences of 52 candidate mutants (serial numbers 1-52) and 6 control sequences (serial numbers 53-58) all contain the above three mutations, and other mutation forms are shown in the table below).
[0280] A total of 52 candidate mutant antigen sequences (serial numbers 1-52) and 6 control sequences (serial numbers 53-58), 1 wild sequence (serial number 59), and 1 positive control (serial number 60) were designed using a variety of mutation combinations. The specific mutation combinations of the mutants are shown in the table below.
[0281] The positive control comes from Pfizer's already marketed vaccine Abrysvo TM (NDC 0069-0344-05), which is different from the mRNA vaccine designed in the present invention, is a protein vaccine.
[0282] Design ideas for control sequences: Based on the mutants designed in this application, different control sequences were designed to explore the effects of mutations at different sites. For example,
[0283] ① In order to explore the impact of mutations in groups 2 and 3 in site mutations, PC-RSV-063 was designed based on the YK-RSV-003 mutation combination.
[0284] ② To explore the effects of mutations in group 1 among site mutations, based on the YK-RSV-061 mutation combination, the mutation types in group 1 were changed to design PC-RSV-067 and PC-RSV-068;
[0285] ③ In order to explore the impact of mutations in group 2 and group 3 among site mutations, PC-RSV-064, PC-RSV-065, and PC-RSV-066 were designed based on the YK-RSV-061 mutation combination.
[0286] 1. Refer to "Design cycle 4, RSV F variant: sc9-10 DS-Cav1 A149C" in "M Gordon Joyce et al., Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV, Nature Structural&MolecularBiology volume 23, 811–820 (2016), doi:10.1038 / nsmb.3267" Y458C S46G K465Q S215P E92D; Mutations: A149C, S155C, S190F, V207L, S290C, L373R, Y458C, S46G, K465Q, S215P, E92D; F1-F2 Linker residues: 103-145; Linker sequence: GS; End residue: 513", design mutant PC-RSV-063.
[0287] 2. Design mutant PC-RSV-064 with reference to "Sequence No. 6" in the patent application disclosure "WO2023 / 166079 A1".
[0288]
[0289]
[0290]
[0291]
[0292] 1.2 Example 2: Preparation of RSV F antigen mRNA vaccine
[0293] After designing the antigen sequence, it was synthesized into the vector pVaX1, which has an optimized 5'-UTR, 3'-UTR and polyA tail. All plasmids were synthesized by Anshengda Biotechnology Co., Ltd. The synthetic plasmid was linearized and digested, and the mRNA stock solution was prepared by in vitro transcription, and LNP was encapsulated to obtain the mRNA preparation sample.
[0294] Among them, the mRNA transcribed with pVaX1 as the basic skeleton is used for subsequent Western Blot, flow cytometry analysis of antigen epitope binding, ELISA detection of antigen epitope binding, and BLI detection of antigen-antibody affinity. HIS-tag and T4 fibritin fold are added to the vector skeleton for stability testing of secretory protein trimer formation.
[0295] The specific preparation process of mRNA samples is described as follows.
[0296] 1.2.1 Preparation of mRNA stock solution
[0297] 1) Experimental Materials
[0298] NEB ® Golden Gate Assembly Kit (BsaI-HFv2) (NEB, Cat. No.: R3733);
[0299] DNA product purification kit (purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd. (referred to as Tiangen), Cat. No.: DP205);
[0300] ATP (purchased from Shanghai Zhaowei Biotechnology Co., Ltd. (referred to as Zhaowei), Cat. No.: R1-051);
[0301] CTP (Megadimensional, Cat. No.: R3-056);
[0302] GTP (Megadimensional, Cat. No.: R2-057);
[0303] N1-Me-pUTP (Megadimensional, Cat. No.: R5-064);
[0304] Cap1-GAG m7G(5')ppp(5')(2'OMeA)pG (Mega Dimension, Cat. No.: ON-134);
[0305] T7 RNA polymerase (Zhaowei, Cat. No.: ON-004);
[0306] RNase Inhibitor (Zhaowei, Cat. No.: ON-039);
[0307] Pyrophosphatase (Zhaowei, Cat. No.: ON-025);
[0308] 10× IVT reaction buffer (MegaVit, Cat. No.: ON-062);
[0309] DNase I (Mega-Vis, Cat. No.: ON-109).
[0310] 2) Experimental process
[0311] ① Plasmid linearization
[0312] The plasmid DNA was linearized with BsaI-HFv2 endonuclease. The restriction enzyme system included the plasmid DNA inserted with the target gene, 10 × rCutSmart buffer, BsaI-HFv2, and sterile enzyme-free water (RNase-free ddH 2 O). The enzyme digestion reaction temperature is 37 °C, the enzyme digestion time is 15-30 min, and the enzyme digestion system is shown in the table below.
[0313]
[0314] After the enzyme digestion reaction was completed, the linearized product was recovered using a DNA product purification kit, the product concentration was determined using an ultra-micro UV spectrophotometer (Denovix), and the length and state of the linearized plasmid template were detected by agarose gel.
[0315] ② Co-transcriptional capping
[0316] The linearized plasmid prepared in the above step is used as a template, and NTP solution (NTPs) and cap1 cap analog are used as starting materials to transcribe and synthesize mRNA by T7 RNA polymerase. The cap1 cap analog is Cap1-GAG, which has a structure of m7G (5') ppp(5') (2'-OMeA) pG, and its molecular formula is C 32 H 43 N 15 O 24 P 4 .
[0317] The specific reaction system is shown in the table below. The prepared reaction system was placed in a 37 °C incubator for 3 h with shaking.
[0318]
[0319] Add 1 μl of DNase I to the 20 μl co-transcription capping reaction system after the above reaction is completed, mix well and digest at 37 °C for 30 min to obtain the co-transcription capping product.
[0320] ③ LiCl precipitation purification
[0321] The co-transcription capping product obtained above was purified by lithium chloride precipitation method as follows:
[0322] Add LiCl: Add LiCl to the co-transcription capping product to a final concentration of 2.8 M and cryoprecipitate for 2 h.
[0323] Precipitation: Centrifuge at 12000 rpm for 15 min and retain the precipitate.
[0324] Washing: Wash twice with 75% ethanol and dissolve with sterile enzyme-free water to obtain mRNA stock solution.
[0325] Detection: The concentration of the purified transcripts was measured by ultraviolet spectrophotometer (Denovix), and the integrity was checked by capillary electrophoresis.
[0326] 1.2.2 Preparation of mRNA-LNP (mRNA vaccine)
[0327] Accurately weigh cationic lipids, DSPC, cholesterol, and DMG-PEG2000 respectively, add anhydrous ethanol to dissolve, and prepare a carrier mixed solution according to the molar ratio (the molar ratio of cationic lipids, neutral lipids, structural lipids and polymer conjugated lipids is controlled to be 49:10:39.5:1.5) as an organic phase for later use.
[0328] Dissolve mRNA in citrate buffer and dilute to prepare a solution as the aqueous phase. TM The syringes extracted the organic phase and the aqueous phase respectively, the left pump was placed with the organic phase, and the right pump was placed with the aqueous phase to prepare the LNP intermediate solution in the microfluidic device.
[0329] The above LNP intermediate solution was diluted with PBS solution, concentrated by ultrafiltration on an ultrafiltration device, and after being concentrated to a certain volume, PBS solution was added to dilute it and concentrated on an ultrafiltration device. The ultrafiltration was stopped when the final concentrated volume was less than 5 ml.
[0330] 1.3 Example 3: Western Blot Detection of RSV F Antigen Mutant Expression
[0331] In order to verify whether the designed antigen mRNA can be expressed in cells, the mRNA was transfected into cells, and Western Blot was used to detect the expression of the antigen mRNA in cells.
[0332] 1) Experimental Materials
[0333] 293T cells (purchased from ATCC cell bank);
[0334] Primary antibody: HRSV-F (purchased from Beijing Tiancheng Biotechnology (Beijing) Co., Ltd., hereinafter referred to as Beijing Tiancheng, Cat. No.: 11049-R302);
[0335] Secondary antibody: Goat Anti-Mouse IgG (H+L) Secondary Antibody, HRP (purchased from Shanghai Biotime Biotechnology Co., Ltd., hereinafter referred to as Biotime, Cat. No.: A0286);
[0336] Experimental group: protein sample mixture obtained by lysing cells transfected with the series of mRNA vaccines prepared in Example 2;
[0337] Internal reference protein: glyceraldehyde-3-phosphate dehydrogenase GAPDH;
[0338] 2) Experimental process
[0339] Cell culture and transfection: 293T cells were cultured at 1.3 × 10 5 / well were inoculated into 24-well plates. On the next day, mRNA-LNP samples (containing 300 ng of mRNA) were directly added to the cells and mixed evenly.
[0340] Protein sample preparation: ① After 16 hours of transfection, the cells were taken out of the incubator, and the cells were repeatedly pipetted to make all the cells detach from the bottom of the dish. The cells were transferred to a 1.5 ml centrifuge tube and centrifuged at 25 °C, 1500 rpm for 3 min. ② Discard the supernatant, add 1 ml PBS and resuspend the cells by pipetting; centrifuge, centrifuge, 1500 rpm for 3 min. ③ Repeat the previous step twice. ④ Add 50 μl RIPA lysis buffer to each tube of cells (add 0.5 μl 100× protein inhibitor to RIPA lysis buffer before use), place on ice for 30 min, and vortex the sample for 30 s every 5 min. ⑤ Pre-cool the centrifuge, after the cells are fully lysed, the sample is centrifuged at 4 °C, 12000 rpm for 10 min, and the supernatant is transferred to a new 1.5 ml centrifuge tube to obtain the protein sample to be tested.
[0341] Development and analysis: Use BCA quantitative kit to detect the concentration of protein samples. Pipette samples for spotting, spot 4 μl of marker, and electrophoresis at 200V for 30 min. Use dry transfer instrument for transfer, take out the gel and make a transfer "sandwich", cover the negative plate, transfer at 21V, 23V, and 25V for 1, 4, and 2 min respectively; then block at room temperature for 1 h. Primary antibody incubation: Incubate at room temperature for 1 h. Washing membrane: Use 1×TBST buffer solution as washing solution, 5 min / time, 3 times. Secondary antibody incubation: Incubate at room temperature for 1 h. Washing membrane: Use 1×TBST buffer solution for washing, 5 min / time, 3 times. Color development: Mix 1 ml of developer and fixer in a 1:1 ratio, add to the membrane for color development, and take pictures.
[0342] 1.4 Example 4: Flow cytometry detection of RSV F antigen mutant Φ and II epitope binding
[0343] To explore whether RSV F antigen mutants have prefusion epitopes, in this example, RSV pre-F antibody (3C12) (specifically binds to RSV pre-F Φ epitope) and RSV F antibody (11A9) (binds to pre-F and post-F II epitopes) were used for flow cytometry detection. RSV F protein mutants in the pre-F conformation are expected to bind to the tested antibodies.
[0344] 1) Experimental Materials
[0345] 293T cells (purchased from ATCC cell bank); RSV pre-F antibody (3C12), Φ epitope (Epitope Φ) (nearshore protein, Cat. No.: DA101); RSV F antibody (11A9), II epitope (Epitope II) (nearshore protein, Cat. No.: DA091);
[0346] Experimental group: mRNA vaccine corresponding to the antigen expressed in Example 3;
[0347] 2) Experimental process
[0348] ① Cell transfection: 293T cells were transfected at 1.3×10 5 / well were inoculated into 24-well plates. On the next day, mRNA-LNP samples (containing 300 ng of mRNA) were directly added to the cells and mixed evenly.
[0349] ② Cell collection: 16 hours after transfection, remove the cells from the incubator, use a pipette to discard the culture medium, use a pipette to absorb 500 μl of 0.1% BSA solution to wash the remaining culture medium in the well plate, be careful not to blow up the cells, and use a pipette to discard the 0.1% BSA solution. Add 500 μl of 0.1% BSA solution to each well, blow the cells and transfer them to a 1.5 ml centrifuge tube.
[0350] ③ Centrifugation: Protect from light, harvest the cells by centrifugation at 400 g for 5 min at 4 °C, and discard the supernatant.
[0351] ④ Staining: Add 50.6 μl of RSV fluorescent antibody dilution solution to the control and test samples respectively to resuspend the cells, and incubate the samples at 4 °C in the dark for 2 h.
[0352] ⑤ Washing: After incubation, add 500 μl of 0.1% BSA solution to each tube of sample, protect from light, centrifuge at 400g for 5 min at 4°C to harvest the cells, and discard the supernatant. Repeat this operation three times.
[0353] ⑥ Resuspend cells: Add 200 μl of 0.1% BSA solution to each sample and carefully pipette the cells to make a cell suspension.
[0354] ⑦ Flow cytometry: Flow cytometry was used to measure the binding kinetics of RSV F mutants and antibodies. 1×10 4 cells.
[0355] 1.5 Example 5: ELISA to detect the stability of RSV F antigen mutants
[0356] In order to explore the stability of RSV F antigen mutants under different pH, temperature, osmotic pressure and other conditions, this example conducted stress tests on the mutants under different treatment conditions.
[0357] 1) Experimental Materials
[0358] 293T cells (purchased from ATCC cell bank);
[0359] Primary antibody: RSV pre-F antibody (3C12), Φ epitope (purchased from Suzhou Jinan Protein Technology Co., Ltd. (Jinan for short), Cat. No.: DA101);
[0360] Standard: RSV pre-F trimer protein (RSV pre-F Trimer Protein) (Nearshore, Cat. No.: DRA230);
[0361] Secondary antibody: Peroxidase AffiniPure Goat Anti-Human IgG (H+L) (purchased from Yisheng Biotechnology (Shanghai) Co., Ltd. (referred to as Yisheng), Cat. No.: N / A);
[0362] Experimental group: mRNA vaccine after screening in Example 4;
[0363] 2) Experimental process:
[0364] ① Cell transfection and collection: The transfection steps are the same as in Example 3, and the cell supernatant is collected.
[0365] ② Different pH conditions: The RSV F protein solution was adjusted to pH 3.5 and pH 10 with 10% NaOH and 1 M HCl solutions, respectively, and incubated at room temperature for 60 min, then neutralized to pH 7.4.
[0366] ③ High temperature treatment: RSV F protein solution was incubated at 50°C for 60 min.
[0367] ④ Low temperature treatment: RSV F protein solution was stored at 4°C for one week.
[0368] ⑤ Hypoosmotic pressure treatment: The cell supernatant contained 110 mM NaCl, which was diluted to 10 mM NaCl with 2.5 mM Tris buffer (pH 7.5) and incubated at room temperature for 60 min.
[0369] ⑥ Hyperosmotic pressure treatment: Cell supernatant was treated with 4.5 M MgCl 2 Adjust to 3.0 M MgCl 2 , and incubate at room temperature for 60 min.
[0370] ⑦ ELISA detection of antigen expression:
[0371] Coating: Add the coating working solution to a 96-well ELISA plate and place at 2 °C ~8 °C for 16 h~20 h.
[0372] Wash the plate: Add phosphate buffered saline (PBST) to each well, wash the plate using a plate washer, wash the plate 5 times, and pat dry on absorbent paper.
[0373] Blocking: After adding blocking solution, place on the ELISA constant temperature oscillator at 37 °C, 400 rpm, and incubate for 1.5 h.
[0374] Wash the plate: Add PBST solution to each well and wash the plate using a plate washer. Wash the plate 5 times and pat dry on absorbent paper.
[0375] Primary antibody incubation: Add primary antibody dilution to each well, seal the plate with sealing film, and incubate at 37 °C, 400 rpm for 1.5 h.
[0376] Wash the plate: Add PBST solution to each well and wash the plate using a plate washer. Wash the plate 5 times and pat dry on absorbent paper.
[0377] Secondary antibody incubation: Add secondary antibody dilution to each well, seal the plate with sealing film, and incubate at 37 °C 400 rpm for 45 min.
[0378] Wash the plate: Add PBST solution to each well and wash the plate using a plate washer. Wash the plate 5 times and pat dry on absorbent paper.
[0379] Color development: Add color developing solution, seal the plate with sealing film, and incubate on an ELISA thermostat at 37 °C, 400 rpm for 25 min.
[0380] Termination reaction: After color development is completed, add 50 μl / well of stop solution to the ELISA plate to terminate the reaction.
[0381] Read the plate: Use a multifunctional microplate reader, set the dual wavelengths of 450 nm and 630 nm, and read the absorbance value (OD value) within 5 minutes.
[0382] 1.6 Example 6: ELISA detection of different epitope binding of RSV F antigen mutants
[0383] In order to explore the binding between RSV F antigen mutants and antibodies recognizing different epitopes, this example uses the ELISA method to measure the binding amount.
[0384] 1) Experimental Materials
[0385] 293T cells (purchased from ATCC cell bank);
[0386] Primary antibody: RSV pre-F antibody (3C12), Epitope Φ (Near Shore, Cat. No.: DA101);
[0387] RSV pre-F antibody (7H11), Quaternary epitope (Epitope Quaternary) (Near Shore, Cat. No.: DA109);
[0388] RSV F antibody (11A9), Epitope II (Near Shore, Cat. No.: DA091);
[0389] RSV F antibody (4B9), Epitope III (Near Shore, Cat. No.: DA110);
[0390] RSV pre-F antibody (7E11), Epitope V (Cat. No.: DA119);
[0391] Standard: RSV Prefusion F-Trimer Protein (Nearshore, Cat. No.: DRA230);
[0392] Secondary antibody: Peroxidase AffiniPure GoatAnti-Human IgG(H+L) (Yishen, Cat. No.: N / A);
[0393] Experimental group: mRNA vaccine after screening in Example 5;
[0394] 2) Experimental process
[0395] Cell culture and transfection, protein sample preparation: The experimental process is the same as Example 3.
[0396] ELISA detection of antigen expression: The experimental process is the same as Example 5.
[0397] 1.7 Example 7: BLI detection of RSV F antigen mutants and different antibody affinities
[0398] In order to explore the affinity of RSV F antigen mutants and antibodies that specifically recognize pre-fusion conformational epitopes, this example uses the Bio-Layer Interferometry (BLI) method to perform affinity determination.
[0399] 1) Experimental Materials
[0400] 293T cells (purchased from ATCC cell bank);
[0401] RSV pre-F antibody (3C12), Φ epitope (Near Shore, Cat. No.: DA101);
[0402] RSV pre-F antibody (7H11), Quaternary epitope (near shore, Cat. No.: DA109);
[0403] Experimental group: mRNA vaccine after screening in Example 6;
[0404] 2) Experimental process:
[0405] Protein sample preparation: The experimental process is the same as Example 3.
[0406] Each antibody was diluted to 10 µg / ml using 1× PBST solution.
[0407] In 1×PBST solution, ProA probe was used to capture RSV pre-F antibody (3C12) and RSV pre-F antibody (7H11), respectively, with the capture level limited to 4.0 nm; then they were reacted with the diluted target protein in turn, and the solid-phase bound product after sufficient reaction was dissociated and analyzed in 1×PBST buffer.
[0408] The protein interaction instrument was used for detection, and the results were analyzed using Data Analysis 12.0 software to obtain the binding rate, dissociation rate and affinity constant.
[0409] 1.8 Example 8: Study on the immunogenicity of RSV F antigen mutants in mice
[0410] In order to explore the antibody titer produced by RSV F antigen in mice, this example performed in vivo immunization on mice.
[0411] 1.8.1 Immunization of Balb / c mice
[0412] 1) Experimental Materials
[0413] Animals: Balb / c mice, female, 6-8 weeks old;
[0414] Negative control: LNP sample;
[0415] Positive control: Abrysvo TM ;
[0416] Test substance: YK-RSV-001, YK-RSV-011, YK-RSV-030, YK-RSV-036, YK-RSV-044, YK-RSV-060, YK-RS V-062, YK-RSV-061, YK-RSV-003, YK-RSV-012, YK-RSV-015, YK-RSV-039, YK-RSV-054;
[0417] 2) Mouse immunization protocol
[0418]
[0419]
[0420] Note: The dosage volume is calculated based on the actual concentration of the dosage
[0421] 3) Sample collection and pretreatment
[0422] About 0.2 ml of blood was collected from the orbital venous plexus of each animal, and the serum was separated (centrifuged at 4000 rpm / min for 10 min at 4 °C) and stored in a 4 °C refrigerator until processing.
[0423] 4) Health Check
[0424] Once a day, including but not limited to death, morbidity, respiration, secretions, feces, and diet and drinking water.
[0425] 5) Humane End
[0426] According to the IACUC protocol, any mouse that loses more than 20% of its body weight (before infection, the baseline weight is the weight on day 0; after infection, the baseline weight is the weight on the day of infection) or / and shows symptoms of moribundity during the experiment will be euthanized and recorded as a dead animal in the results.
[0427] 1.8.2 Detection of RSV neutralizing antibody titer in mouse serum
[0428] 1) Purpose of testing
[0429] Neutralizing antibody titers against respiratory syncytial viruses RSV A2 and RSV B18357 in serum were measured using a plaque reduction-based microneutralization assay.
[0430] 2) Key reagents
[0431] Primary antibody: Research Grade Palivizumab (purchased from Wuhan Costan Biotechnology Co., Ltd., hereinafter referred to as Wuhan Costan, Cat. No.: CSD00024);
[0432] Secondary antibody: rabbit anti-human IgG H&L (HRP) (Abcam, Cat. No.: ab6759);
[0433] 3) Data calculation formula:
[0434] ① Sample inhibition rate: calculated by Excel (single-well calculation), sample inhibition rate = (1-(number of sample spots / number of virus control spots)) × 100%.
[0435] ② Set the sample dilution multiple as the X-axis and the inhibition rate as the Y-axis, input into GraphPad software, and use four-parameter fitting to calculate the IC of the sample 50 The IC50 value is the neutralizing antibody titer of the sample. The titer is rounded to integers, and the linear correlation coefficient R2 is rounded to two decimal places.
[0436] ③ Average value: , X i Indicates the value of the nth measurement, n indicates the number of measurements; calculated by Excel, retained to the second decimal place. Note: If the calculated result is a titer value, retain the integer.
[0437] 4) Experimental process
[0438] After gradient dilution of the serum sample to be tested, a certain amount of RSV virus is added, and after neutralization reaction, the mixture is added to the cell plate for culture for 22-26 hours, and the neutralizing antibody titer level of the serum sample is finally calculated based on the formation of spots. The operation process is as follows:
[0439] Cell preparation and plate seeding: HEp-2 cells were purchased from Shanghai Yuchi Biotechnology. They were revived and cultured before the experiment. The passages used for testing were 3 to 20 after revivification. The cells were digested and seeded into 96-well plates in advance, with 2.5×10 5 cells / ml, 0.1ml / well, incubated at 37 °C, 5% CO 2 Incubate the cells for 17-23 hours. After confirming that the cells are normal, take serum samples and dilute them according to the gradient.
[0440] Set up controls: Set up controls in a 96-well plate (neutralization plate). Add diluents to the cell control (CC) and virus control (VC), and set up duplicate wells for each.
[0441] Virus addition: Take the diluted virus and add it to the sample well and VC well of the 96-well plate. Tap the 96-well plate to mix the sample and virus. Place it in a 37 °C, 5% CO 2 Incubate in an incubator for neutralization reaction.
[0442] Cell preparation, infection and culture: Take the 96-well plate inoculated with cells in advance, discard the original culture medium, take the neutralization plate mixture and add it to the 96-well plate with cells, and place it in a 37 °C, 5% CO 2 Culture in incubator.
[0443] Fixation and staining: After incubation, discard the original culture medium and add a certain volume of fixative to each well. After fixation, discard the fixative and wash twice with 1×PBS. After adding blocking solution, discard the blocking solution and wash twice with 1×PBS; after adding primary antibody working solution for incubation, discard the antibody and wash twice with 1×PBS; after adding HRP secondary antibody working solution for incubation, discard the antibody and wash twice with 1×PBS; add color developing solution and incubate at room temperature for 5-20 min; discard the color developing solution, pat dry, and count the spots with ELISA spot analyzer.
[0444] Result calculation: Neutralizing antibody titer: Calculate the inhibition rate of each gradient of the sample, input the sample dilution multiple-inhibition rate into GraphPad software for fitting, and calculate the IC of the sample 50 and IC 90 Value, IC 50 and IC 90 The value is the neutralizing antibody titer of the sample.
[0445] 1.8.3 Detection of RSV binding antibody titer in mouse serum
[0446] 1) Purpose of testing
[0447] A validated self-built indirect ELISA method was used to test serum samples in the RSV mRNA vaccine immunogenicity test. The detection indicators included RSV pre-F and post-F protein-specific antibody titers, providing data support for the analysis of vaccine immunogenicity and protection against virus infection.
[0448] 2) Key reagents
[0449] Coating working solution: RSV-pre-F-11 protein (Vazyme, Cat. No.: RM2187); RSV-post-F-11 protein (Vazyme, Cat. No.: RM2188);
[0450] Positive quality control: RSV-pre-F0 specific monoclonal antibody (Monoclonal Anti-RSV-pre-F0 specificAntibody*) (Acro, Cat. No.: RS0-Y132); RSV-post-F0 specific monoclonal antibody (Monoclonal Anti-RSV-post-F0 specific Antibody*) (Acro, Cat. No.: RSV-Y180);
[0451] Secondary antibody: HRP-labeled rabbit anti-mouse IgG secondary antibody (Rabbit Anti-Mouse IgG HL (HRP)) (Abcam, Ab6728);
[0452] 3) Data calculation formula
[0453] Mean: Mean=Average(OD value X1:OD value Xn);
[0454] Signal-to-noise ratio (SNR): SNR = sample average OD value / NC average OD value;
[0455] Coefficient of variation (CV%): CV%=STDEV(OD value X1: OD value Xn) / average OD value*100;
[0456] Combined antibody titer calculation: Use the FORECAST(x, known_y's, known_x's) function to calculate the titer value in each analysis batch, where x is the Cut off value, known_y's are the two dilution factors spanning the Cut off value, and known_x's are the two OD values spanning the Cut off value. The corresponding dilution factor obtained is the titer value of each sample.
[0457] 4) Experimental process
[0458] The same ELISA detection method as in Example 5 was used. In the primary antibody incubation step, the diluted serum sample to be tested was added, the plate was sealed with a sealing film, and then placed on an ELISA thermostatic oscillator at 37 ° C, 400 rpm, and incubated for 1.5 h.
[0459] 1.9 Example 9: Study on the immunogenicity of RSV F antigen mutants in cotton rats
[0460] In order to explore the antibody titer produced by RSV F antigen in cotton rats and the immune protection effect after virus challenge, cotton rats were immunized in vivo in this example.
[0461] 1.9.1 Cotton rat immunization
[0462] 1) Experimental Materials
[0463] Animals: Cotton rats, female, 6-8 weeks;
[0464] Negative control: LNP sample;
[0465] Positive control: Abrysvo TM ;
[0466] Test substances: YK-RSV-001, YK-RSV-061, YK-RSV-062, YK-RSV-003, YK-RSV-012, YK-RSV-015, YK-RSV-036, YK-RSV-039, YK-RSV-044, YK-RSV-054, YK-RSV-060;
[0467] 2) Cotton rat vaccination program
[0468]
[0469] Note: The dosage volume is calculated based on the actual concentration of the dosage. TM The injection dose includes 25 μg each of type A and type B.
[0470] 3) Tissue sample collection
[0471] On the 54th day, the lungs and nasal concha were removed aseptically.
[0472] 4) Attack information
[0473] On the 49th day, the virus was challenged by intranasal drops with RSV A2 virus in a volume of 50 μl (5×10 5 PFU).
[0474] 1.9.2 Determination of RSV binding and neutralizing antibody titers in cotton rat serum
[0475] The method for detecting binding antibody and neutralizing antibody titers is the same as in Examples 4.8.2 and 4.8.3.
[0476] 1.9.3 Plaque assay for detection of RSV titer in cotton rat tissue samples
[0477] 1) Purpose of testing
[0478] The plaque assay was used to determine the respiratory syncytial virus (RSV) titer in the left lung and nasal turbinates of cotton rats to complete the testing of all biological samples.
[0479] 2) Key reagents
[0480] Primary antibody: Palivizumab (Research Grade Palivizumab) (Wuhan Costan, Cat. No.: CSD00024);
[0481] Secondary antibody: rabbit anti-human IgG H&L (HRP) (Abcam, Cat. No.: ab6759);
[0482] Quality control virus RSV A2;
[0483] 3) Experimental process
[0484] The cells are infected by gradient dilution of the sample to be tested, and after removing the infection solution, the covering solution is added and cultured until plaques are formed. The virus titer in the tissue sample is finally calculated based on the appearance of plaques or lesions. The operation process is as follows:
[0485] Cell preparation and plate seeding: HEp-2 cells were purchased from Shanghai Yuchi Biotechnology. They were revived and cultured before the experiment. The passages used for testing were 3 to 20 after revivification. The cells were digested and seeded into 24-well plates in advance, with 2×10 5 cells / ml, 1 ml / well, incubate at 37 °C, 5% CO 2 Incubate incubator for 17 h~23 h.
[0486] Tissue sample processing: After obtaining left lung and nasal turbinate tissue samples, add virus maintenance solution, grind the tissue, centrifuge the samples to obtain the supernatant, and perform gradient dilution.
[0487] Cell treatment: Take out the pre-seeded cell plate from the 37°C CO2 incubator, discard the culture supernatant, add 1×PBS and wash twice, and discard the remaining liquid;
[0488] Virus infection and adsorption: Take the supernatant of the diluted tissue homogenate and add it to the corresponding wells of the cell plate. Place the 24-well plate in a 37 °C, 5% CO 2 Incubator to allow the virus to fully adsorb to the cells;
[0489] Add covering layer: After adsorption, discard the virus solution, add covering layer to each well, and place the cell plate in 37 °C, 5% CO 2 The cells were cultured in an incubator and the lesions and plaque formation were observed daily;
[0490] Fixation: After typical plaques appear in the virus wells, discard the cover layer and add 4% paraformaldehyde to each well for fixation;
[0491] Staining: After the cell plate is fixed, the fixative solution is discarded, and the cells are washed three times with 1×PBS, and the blocking solution is added for blocking; the blocking solution is discarded, and the cells are washed three times with 1×PBS, and the primary antibody working solution is added for incubation; the antibody is discarded, and the cells are washed three times with 1×PBS, and the HRP secondary antibody working solution is added for incubation; the antibody is discarded, and the cells are washed three times with 1×PBS, and the color developing solution is added, and the cells are incubated at room temperature for 10-20 minutes; the color developing solution is discarded, and the spots are observed and counted using a film camera;
[0492] Calculation results:
[0493] Virus titer [PFU / mL] = (average number of plaques × sample dilution multiple) / inoculum volume (mL);
[0494] Tissue virus titer [PFU / g] 1* =[(average number of plaques × dilution factor of tissue sample) / inoculation volume (mL) × volume of tissue grinding solution (mL)] / tissue weight (g).
[0495] The tissue virus Lg titer [Lg PFU / g] is the logarithm of the tissue virus titer [PFU / g] to the base 10.
[0496] 1*: All plaques of all dilutions that can be accurately counted are selected for statistical calculation, and the arithmetic mean is used for calculation.
[0497] 1.9.4 HE staining to detect inflammatory markers in lung tissue
[0498] 1) Purpose of testing
[0499] HE staining was used to detect inflammatory markers in lung tissue.
[0500] 2) Key reagents
[0501] Xylene solution (Shanghai Zhanyun Chemical Co., Ltd., Cat. No.: 1330-20-7); Hematoxylin solution (Mayer) (Beso, Cat. No.: BASO-BA-4021); Eosin solution (alcohol soluble) (Beso, Cat. No.: BASO-BA-4022);
[0502] 3) Experimental procedures
[0503] After perfusion, the lung tissue was fixed in 4% paraformaldehyde for more than 24 hours, dehydrated, and sliced at the maximum parenchymal area with a slice thickness of 4 μm. The staining rack loaded with the slices was placed in a 60-65 °C oven for 1 hour to bake the slices. After the paraffin melted into a transparent liquid, the staining rack was placed at room temperature for 10 minutes to cool. After cooling, HE staining was performed and finally the slices were sealed.
[0504] 4) Results
[0505] Manual semi-quantitative scoring was performed, and the scoring criteria are shown in the following table. Data were analyzed using Mean + SEM statistics and one-way ANOVA.
[0506]
[0507] 2. Results Analysis
[0508] 2.1 Expression results of RSV F antigen mutants
[0509] YK-RSV-001, YK-RSV-002, YK-RSV-003, YK-RSV-004, YK-RSV-005, YK-RSV-008, YK-RS V-009, YK-RSV-010, YK-RSV-011, YK-RSV-012, YK-RSV-013, YK-RSV-014, YK-RSV-015 , YK-RSV-016, YK-RSV-017, YK-RSV-018, YK-RSV-019, YK-RSV-022, YK-RSV-029, YK-R SV-030, YK-RSV-031, YK-RSV-032, YK-RSV-033, YK-RSV-034, YK-RSV-035, YK-RSV-03 6. YK-RSV-037, YK-RSV-038, YK-RSV-039, YK-RSV-040, YK-RSV-041, YK-RSV-042, YK- RSV-043, YK-RSV-044, YK-RSV-045, YK-RSV-046, YK-RSV-048, YK-RSV-050, YK-RSV-0 51, YK-RSV-052, YK-RSV-053, YK-RSV-054, YK-RSV-055, YK-RSV-056, YK-RSV-057, YK-RSV-058, YK-RSV-059, YK-RSV-060, YK-RSV-061 and YK-RSV-062 mutants all had obvious protein expression, with a size of about 75 kDa, which is consistent with the theoretical size of the antigen and can be used as effective candidate antigens for the next step of immunogenicity screening and evaluation. Therefore, the above 50 mutants will be further screened by determining antigen epitope binding by flow cytometry.
[0510] 2.2 RSV F antigen mutant epitope binding assay results
[0511] Among the major neutralizing active antigenic epitopes of RSV F protein, the Φ epitope is only located in the prefusion conformation, while the II epitope is retained in both the prefusion and postfusion conformations.
[0512] The ability of antibodies to specifically bind to the Φ epitope is related to neutralization activity. A low binding rate to the Φ epitope in turn affects the neutralization activity, resulting in poor neutralization activity.
[0513] The RSV pre-F antibody (3C12) used in this example specifically binds to the RSV pre-F Φ epitope, and the RSV F antibody (11A9) binds to the pre-F and post-F II epitopes. The binding of the Φ epitope and the II epitope on the mutant to the corresponding antibody 3C12 and 11A9 epitopes, respectively, can be detected by flow cytometry, and whether the RSV F mutant pre-fusion conformation is stable can be further inferred. The epitope binding data are shown in the following table.
[0514]
[0515]
[0516] There are 20 mutants on RSV F mutants whose binding rate with antibody 3C12 is higher than 90%. The binding rate of Φ epitope on these mutants with antibody 3C12 is better than that of control PC-RSV-064, PC-RSV-065, PC-RSV-066, PC-RSV-067, PC-RSV-068 and wild-type RSV A2 (138251)-wt.
[0517] 1) The binding rate of the Φ epitope on the following 11 RSV F mutants to antibody 3C12 was higher than 90%, ranging from 91.6% to 94.9%, and was significantly better than the control
[0518] The mutants within this range are shown in the table below, including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060.
[0519]
[0520] 2) The binding rates of the Φ epitope on the following 9 RSV F mutants to antibody 3C12 were also higher than 90%, and were significantly better than the control
[0521] The binding rates of the Φ epitope on the 9 mutants in the table below to the antibody 3C12 are 90.3% to 94.6%, and the mutants within this range are shown in the table below.
[0522]
[0523]
[0524] 3) The binding rate of the Φ epitope on the following 15 RSV F mutants to antibody 3C12 was 80% to 90%, which was better than the control or equivalent to it
[0525] The mutants within this range are shown in the table below. The binding rates of the Φ epitope on these mutants to the antibody 3C12 are 81.2% to 89.6%, the binding rates of the Ⅱ epitope to the antibody 11A9 are 88.7% to 95.1%, and the Φ / Ⅱ ratio is 90.7% to 95.4%.
[0526]
[0527] There are 15 mutants on the RSV F mutants whose binding rate to the Φ epitope of antibody 3C12 is less than 80%.
[0528] 4) The binding rate of the Φ epitope on the seven RSV F mutants to antibody 3C12 was less than 80%
[0529] The binding rates of the Φ epitope on the following 7 mutants to antibody 3C12 were 76.8% to 79.8%, the binding rates of the Ⅱ epitope to antibody 11A9 were 83.4% to 87.1%, and the Φ / Ⅱ ratios were 88.2% to 95.7%. The mutants within this range are shown in the table below.
[0530]
[0531] In summary, the binding rate of the Φ epitope on the 42 mutants screened above (see Tables 8, 9, 10 and 11) to the corresponding antibodies is relatively high.
[0532] 2.3 Results of stability screening of RSV F antigen mutants
[0533] The RSV F prefusion conformation is in a metastable state and can spontaneously rearrange into a highly stable postfusion conformation. The triggering factors for the transition from the prefusion conformation to the postfusion conformation during cell entry are unclear. However, when the F protein is extracted from the membrane with surfactants such as Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octyl glucoside, octyl thioglucoside, SDS, CHAPS, CHAPSO, or expressed as an extracellular domain, the F glycoprotein is easily converted to a postfusion conformation after physical or chemical stress or storage (JS McLellan et al., 2013; JO Ngwuta et al., 2015). RSV F in the prefusion conformation helps the vaccine to induce or enhance neutralization activity, and physical stability directly affects the protein conformation. Therefore, this example screens antigens with better stability through different treatment conditions.
[0534] In this example, the stability screening of mutants under different treatment conditions is defined as stress testing, which includes low-temperature storage at 4°C for one week; incubation at 50°C for 60 min; low osmotic pressure and high osmotic pressure treatment at room temperature for 60 min; acid and alkaline treatment at room temperature for 60 min. ELISA detection of mutants binding to RSV pre-F antibody (3C12) that recognizes the Φ epitope. The stress resistance parameter in this example is calculated as follows:
[0535] Stress resistance parameter = the amount of antibody binding to the stressed sample ÷ the amount of antibody binding to the unstressed sample;
[0536] More stable mutants are expected to have higher stress resistance. The stability screening results are as follows:
[0537] 1) Under different stress tests, the mutants retained the ability to bind to antibodies.
[0538] Judging from the ELISA test results, the mutant still maintains affinity with RSV pre-F antibody (3C12) after different stress tests, because RSV pre-F antibody (3C12) specifically binds to the Φ epitope of the pre-fusion conformation of RSV F protein, indicating that after different stress tests, the mutant can still be stabilized in the pre-fusion conformation.
[0539] 2) Some mutants remain very stable after stress testing.
[0540] Through inter-group analysis of the stability results of all mutants, it was found that the stress resistance parameters were lower than 0.4 after storage at 4°C for one week, lower than 0.5 after incubation at 50°C for 60 min, lower than 0.5 after high osmotic pressure treatment for 60 min, and lower than 0.5 after low osmotic pressure treatment for 60 min. The mutants showed relatively significant differences among the groups and were therefore used as standards for antigen screening.
[0541]
[0542] .
[0543] The stress resistance parameters of the following mutants were above 0.44 and as high as 0.86 after being stored at 4 °C for one week; the stress resistance parameters were above 0.64 after being incubated at 50 °C for 60 min; the stress resistance parameters were above 0.61 after being treated under high osmotic pressure for 60 min; the stress resistance parameters were above 0.70 after being treated under low osmotic pressure for 60 min; the stress resistance parameters were above 0.56 after being treated under pH=3.5 and pH=10 for 60 min. The stress resistance parameters after treatment under different conditions were better than those of the control or equivalent to them.
[0544]
[0545]
[0546]
[0547] 3) Summary:
[0548] ① From the results of physical stability screening, compared with the control, the stability was significantly improved under certain stress tests, and compared with other mutant groups, 20 mutants (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV- 001, YK-RSV-036, YK-RSV-060, YK-RSV-009, YK-RSV-010, YK-RSV-011, YK-RSV-030, YK-RSV-043, YK-RSV-048, YK-RSV-050, YK-RSV-055, YK-RSV-057) have better stability under each stress test, showing strong comprehensive stability. The following ELISA is used to further detect its binding ability with different epitope antibodies.
[0549] 2.4 ELISA results of RSV F antigen mutants and antibodies recognizing different epitopes
[0550] Among the Φ, Quaternary, V, II and III epitopes involved in the present application, compared with the II and III epitopes that exist in both the pre-fusion conformation and the post-fusion conformation, antibodies recognizing the Φ, Quaternary and V epitopes only specifically bind to the pre-fusion conformation, and studies have confirmed that specific epitopes that only exist in the pre-fusion conformation are sensitive sites for neutralizing antibodies and can induce a higher neutralizing antibody response.
[0551] This application uses ELISA to detect the binding of different mutant antigens to antibodies that recognize different epitopes, and the strength of the binding between the antigen and the antibody is measured by the amount of binding. Among them, (1) RSV pre-F antibody (3C12) that recognizes the Φ epitope only binds to the F protein in the pre-fusion conformation; (2) RSV pre-F antibody (7H11) recognizes the Quaternary epitope (spanning the IV and V epitopes) and specifically binds to the F protein in the pre-fusion conformation; (3) RSV F antibody (11A9) that recognizes the II epitope can simultaneously recognize the pre-fusion and post-fusion conformations of the F protein; (4) RSV F antibody (4B9) that recognizes the III epitope prefers to recognize the pre-fusion conformation and has weaker binding activity with the post-fusion conformation; (5) RSV pre-F antibody (7E11) that recognizes the V epitope only binds to the F protein in the pre-fusion conformation. The ELISA test results are shown below.
[0552]
[0553]
[0554] 1) The Φ epitope, Quaternary epitope, and V epitope on the following 11 mutants can bind well to the corresponding antibodies with strong binding ability. The binding level of II epitope and / or III epitope to the corresponding antibody is better than or equivalent to that of the control.
[0555] For example, the binding level of the Φ epitope on YK-RSV-061, YK-RSV-003, and YK-RSV-062 to the RSV pre-F antibody (3C12) was 1.83 to 2.00 times that of the control PC-RSV-064; the binding level of the Quaternary epitope to the RSV pre-F antibody (7H11) was 2.01 to 2.12 times that of the control PC-RSV-064.
[0556] The binding level of the Φ epitope on YK-RSV-054 to RSV pre-F antibody (3C12) was 2.52 times that of the control PC-RSV-064; the binding level of the Quaternary epitope to RSV pre-F antibody (7H11) was 1.82 times that of the control PC-RSV-064; the binding level of the V epitope to RSV F antibody (7E11) was 3.30 times that of the control PC-RSV-064; the binding level of the II epitope to RSV F antibody (11A9) was 1.79 times that of the control PC-RSV-064; and the binding level of the III epitope to RSV F antibody (4B9) was 2.27 times that of the control PC-RSV-064.
[0557]
[0558] .
[0559] 2) The Φ epitope, Quaternary epitope, and V epitope on the following four mutants can also bind well to the corresponding antibodies, and the binding ability is also strong.
[0560] For example, the binding level of the Φ epitope on YK-RSV-011 to RSV pre-F antibody (3C12) was 2.90 times that of the control PC-RSV-064; the binding level of the Quaternary epitope to RSV pre-F antibody (7H11) was 1.81 times that of the control PC-RSV-064; the binding level of the V epitope to RSV F antibody (7E11) was 2.70 times that of the control PC-RSV-064; the binding level of the II epitope to RSV F antibody (11A9) was 2.09 times that of the control PC-RSV-064; and the binding level of the III epitope to RSV F antibody (4B9) was 2.47 times that of the control PC-RSV-064.
[0561] .
[0562] In summary, the above content detected the binding levels of 5 different epitopes on the mutants with the corresponding antibodies, and the mutants with better binding levels (see Table 16 and Table 17) were further screened as candidate antigens.
[0563] 2.5 Affinity test results of RSV F antigen mutants and antibodies recognizing different epitopes
[0564] Bio-Layer Interferometry (BLI) is a label-free, real-time monitoring optical detection technology, which is mainly used for comprehensive quantitative analysis of biomolecular interactions and protein concentration determination. BLI can monitor the binding process between molecules in real time and calculate the affinity constant (K D ), binding rate constant (K on or k a ), dissociation rate constant (K off , K dis or k d ) and other important data.
[0565] K D =K off ÷ K on ;
[0566] K D : refers to the affinity constant, which indicates the strength of the two bindings, K DThe larger the bond, the weaker it is, and vice versa;
[0567] K on : refers to the binding rate constant;
[0568] K dis (K off ): refers to the dissociation rate constant;
[0569] K on , K off It mainly reflects the mode of molecular interaction, whether it is fast binding and fast dissociation or slow binding and slow dissociation.
[0570] This application uses the BLI method to analyze the affinity of the target protein and two antibodies, among which the RSV pre-F antibody (3C12) recognizes the Φ epitope and the RSV pre-F antibody (7H11) recognizes the Quaternary epitope. The test results are as follows:
[0571]
[0572] .
[0573] 1) The following mutants have the strongest affinity for antibody binding and are significantly better than the control
[0574] The affinity constant K of the Φ epitope on the following mutants binding to RSV pre-F antibody (3C12) D The K of the control group was 3.26E-12~7.79E-11 M, which was significantly lower than that of the control group. D Value (K D is E-10 M, a difference of 1 to 2 orders of magnitude), indicating that the affinity between the antigen and the antibody is strong.
[0575] The affinity constant K of the quadrenary epitope on the mutant binding to RSV pre-F antibody (7H11) D The range was 3.05E-12~6.13E-10 M, except for YK-RSV-044, YK-RSV-060 and YK-RSV-030 and the control K D The K D The values were significantly lower than those of the control (1 to 2 orders of magnitude), indicating that the affinity between the antigen and the antibody was strong.
[0576] The following mutants will be further screened by animal experiments.
[0577] .
[0578] 2.6 Immunogenicity of RSV F antigen mutants in Balb / c mice
[0579] Mice are small in size, grow fast, have low breeding costs, and have a large number of commercially available detection reagents. For these reasons, mice are currently the most widely used animal model for RSV infection. In 1979, Prince first reported mice as an animal model for hRSV infection. The most commonly used are Balb / c mice, which are infected intracavitary with RSV titers of 10 5 ~10 7 PFU, animals can see obvious lower respiratory tract inflammation changes, some cytokines and CC / CXC chemokines such as TNF-α, IL-6, IFN-γ in tracheal perfusion fluid increased significantly, and histopathology showed monocyte (lymphocyte, macrophage) infiltration or interstitial pneumonia around bronchioles and capillaries. The symptoms of mice infected with different RSV subtypes (such as Along, A2 and clinical isolates) are different. After mice are infected with RSV, the respiratory rate is accelerated, accompanied by airway obstruction and airway hyperresponsiveness, and the airway hyperresponsiveness will last for a long time, which is very similar to RSV infection in children. In addition, mice are one of the most commonly used model animals for pharmacological and toxicological studies, with a clear genetic background, many strains, and can meet specific experimental needs through gene targeted transfection or knockout technology. Therefore, the following experiments use mice as animal models for detection.
[0580] 2.6.1 Binding antibody titer test results
[0581] The ELISA method was used to detect the F protein-specific IgG titers before and after fusion in the serum of mice on the 35th day after immunization. The test results are shown in the following table:
[0582] 1. The pre-F IgG antibody titers of the following 11 test substances are Abrysvo TM The positive control was 2.52 ~ 5.31 times, and the post-F IgG antibody titer was Abrysvo TM 1.13 ~5.21 times of the positive control.
[0583] The pre-F IgG antibody titers of YK-RSV-061, YK-RSV-003, and YK-RSV-062 are Abrysvo TM The positive control was 4.29 to 5.31 times higher, and the post-F IgG antibody titer was Abrysvo TM 4.32 ~5.21 times of the positive control.
[0584] Among them, the pre-F IgG antibody titer of the YK-RSV-061 mutant was the highest, and the pre-F IgG antibody titer was as high as Abrysvo TM The post-F IgG antibody titer was 5.31 times that of the positive control. TM5.21 times that of the positive control.
[0585] In all tested substances, the pre-F / post-F ratios were higher than 1, indicating that the pre-fusion conformation F protein produced higher IgG titers than the post-fusion conformation F protein.
[0586]
[0587] .
[0588] 2. YK-RSV-011 and YK-RSV-030, the pre-F IgG antibody titers of both are Abrysvo TM The positive control was 2.38~2.50 times, and the post-F IgG antibody titer was Abrysvo TM 1.30 ~2.81 times of the positive control.
[0589] .
[0590] The immunogenicity of the above test substances will be further evaluated by measuring the level of neutralizing antibodies produced.
[0591] 2.6.2 Neutralizing antibody titer test results
[0592] The neutralizing antibody titer of the serum of mice on the 35th day after immunization was tested by a microneutralization test based on spot reduction. The test results are shown in the following table and Figure 4~Figure 7 (Including Figure (A) and Figure (B) respectively) as shown:
[0593] Neutralizing antibody titers IC of the following 11 test substances 50 For Abrysvo TM 3.72 ~12.67 times of the positive control, IC 90 For Abrysvo TM The levels of leukocytes in the samples were 2.34~14.41 times higher than those in the positive control.
[0594] Neutralizing antibody titers IC of YK-RSV-061, YK-RSV-003 and YK-RSV-062 50 For Abrysvo TM 6.34 ~12.67 times of the positive control, IC 90 For Abrysvo TM The neutralizing antibody titer was significantly higher, ranging from 9.56 to 14.41 times that of the positive control.
[0595] Among them, YK-RSV-061 had the highest neutralizing antibody titer, IC 50 It's Abrysvo TM12.67 times of the positive control, IC 90 It is 14.41 times that of the positive control.
[0596]
[0597] .
[0598] 2. RSV B virus-neutralizing antibody titer results
[0599] The 11 test substances obtained by the above screening were further used to test the neutralizing antibody levels produced by them against RSV B18357 virus. The test results are shown in the following table:
[0600] Neutralizing antibody titers IC of the following 11 mutants 50 For Abrysvo TM 2.85 ~10.63 times of the positive control, IC 90 For Abrysvo TM The neutralizing antibody titers were 2.88 to 14.23 times that of the positive control and were significantly higher than those of the positive control.
[0601] Neutralizing antibody titers IC of YK-RSV-061, YK-RSV-003 and YK-RSV-062 50 For Abrysvo TM 5.68~10.63 times of the positive control, IC 90 For Abrysvo TM The neutralizing antibody titer is very high, ranging from 6.87 to 14.23 times that of the positive control.
[0602] Among them, YK-RSV-061 had the highest neutralizing antibody titer, IC 50 It's Abrysvo TM 10.63 times of the positive control, IC 90 It is 14.23 times that of the positive control.
[0603] .
[0604] In summary, the above 11 test substances (including YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036 and YK-RSV-060) can produce high neutralizing antibody titers against different subtypes of RSV A2 and RSV B18357.
[0605] 2.7 Immunogenicity of RSV F antigen mutants in cotton rats
[0606] In 1971, Dreizin first reported cotton rats as an animal model for hRSV infection. After cotton rats were infected with hRSV, the virus mainly replicated and amplified in the lungs and lower respiratory tract. Pathological examination showed mild to moderate bronchiolitis or pneumonia, airway epithelial cell shedding and atelectasis. The symptoms of upper respiratory tract infection were more obvious, and the changes in related cytokines were not obvious. Cotton rats are a standard animal model for evaluating the effectiveness of vaccines, antiviral drugs and monoclonal antibodies (such as palivizumab). Therefore, the following experiments used cotton rats as an animal model for testing.
[0607] 2.7.1 Binding antibody titer test results
[0608] The ELISA method was used to detect the pre-fusion and post-fusion F protein-specific IgG titers in the serum of cotton rats on days 42 and 48 after immunization (see Figure 8~Figure 11 (Including Figure (A) and Figure (B) respectively), the IgG titer test results on day 42 are shown in the following table:
[0609] (1) On day 42, the pre-F IgG antibody titers of the following 11 test substances were Abrysvo TM The positive control was 3.05~13.10 times, and the post-F IgG antibody titer was Abrysvo TM The levels of TNF-α and TNF-α were 2.36 to 6.38 times of the positive control, which were significantly higher than the positive control.
[0610] The pre-F IgG antibody titers of YK-RSV-061, YK-RSV-003, and YK-RSV-062 are Abrysvo TM The positive control was 9.76~13.10 times, and the post-F IgG antibody titer was Abrysvo TM 4.66~6.33 times that of the positive control.
[0611] Among them, the IgG antibody titer of the YK-RSV-061 test substance was the highest, and the pre-F IgG antibody titer was as high as Abrysvo TM The positive control was 13.10 times, and the post-F IgG antibody titer was Abrysvo TM 6.33 times that of the positive control.
[0612] The pre-F / post-F ratios of all tested substances ranged from 1.39 to 3.95, indicating that the IgG antibody titer produced by the pre-fusion F protein was significantly higher than that produced by the post-fusion F protein.
[0613]
[0614] .
[0615] At the same time, the IgG titer in the cotton rat serum on the 48th day was detected, and the test results are shown in the following table:
[0616] (2) On day 48, the pre-F IgG antibody titers of the following 11 test substances were Abrysvo TM The positive control was 4.44~12.35 times, and the post-F IgG antibody titer was Abrysvo TM The levels of 1.51 to 6.83 times those of the positive control were significantly higher than those of the positive control.
[0617] The pre-F IgG antibody titers of YK-RSV-061, YK-RSV-003, and YK-RSV-062 are Abrysvo TM The positive control was 9.02~12.35 times, and the post-F IgG antibody titer was Abrysvo TM 4.03~6.83 times that of the positive control.
[0618] Among them, the IgG antibody titer of the YK-RSV-061 test substance was the highest, and the pre-F IgG antibody titer was as high as Abrysvo TM The post-F IgG antibody titer was 12.35 times that of the positive control. TM 6.83 times that of the positive control.
[0619] The pre-F / post-F ratios of all tested substances ranged from 1.78 to 4.29 times, indicating that after immunization on the 48th day, the IgG antibody titer produced by the pre-fusion F protein was still significantly higher than that of the post-fusion F protein.
[0620] .
[0621] 2.7.2 Neutralizing antibody titer test results
[0622] Neutralizing antibody titers against RSV A2 virus in cotton rat sera were measured on days 42 and 48 (see Fig.12 (A) and (B), Fig.13 (A) and (B), Fig.16 (A) and (B), Fig.17 (A) and (B)), the results of the 42nd neutralizing antibody titer test are shown in the following table:
[0623] (1) On day 42 after immunization, neutralizing antibody titers IC of the following 11 test substances were detected in cotton rat serum: 50 For Abrysvo TM2.10 ~14.30 times of positive control, IC 90 For Abrysvo TM The levels of leukemia / aspartate amino acids in the samples were 2.26 to 22.33 times of the positive control, which were significantly higher than those in the positive control.
[0624] Neutralizing antibody titers IC of YK-RSV-061, YK-RSV-003 and YK-RSV-062 50 For Abrysvo TM 8.84~14.30 times of the positive control, IC 90 For Abrysvo TM 16.46 ~22.33 times of the positive control.
[0625] Among them, YK-RSV-061 IC 50 It's Abrysvo TM 14.30 times of the positive control, IC 90 The neutralizing antibody titer was 22.33 times that of the positive control.
[0626] .
[0627] (2) At the same time, the neutralizing antibody titer against RSV B virus in the serum of cotton rats on day 42 was tested. The test results are shown in the following table: Fig.14 (A) and (B) and Fig.15 (A) and (B) show:
[0628] Neutralizing antibody titers IC of the following 11 test substances 50 For Abrysvo TM 2.16~14.63 times of the positive control, IC 90 For Abrysvo TM The levels of leukemia / aspartate amino acids in the samples were 2.49 to 17.26 times that of the positive control, which were significantly higher than those of the positive control.
[0629] Neutralizing antibody titers IC of YK-RSV-061, YK-RSV-003 and YK-RSV-062 50 For Abrysvo TM 11.52~14.63 times of the positive control, IC 90 For Abrysvo TM 13.44~17.26 times that of the positive control.
[0630] Among them, YK-RSV-061 IC 50 It's Abrysvo TM 14.63 times of the positive control, IC 90 The neutralizing antibody titer was 17.26 times that of the positive control.
[0631] .
[0632] (3) On the 48th day after immunization, the neutralizing antibody titer against RSV A2 virus in the cotton rat serum was tested. The test results are shown in the following table:
[0633] Neutralizing antibody titers IC of the following 11 test substances 50 For Abrysvo TM 1.70 ~7.57 times of positive control, IC 90 For Abrysvo TM The levels of leukocytes in the samples were 1.46~11.56 times higher than those in the positive control.
[0634] Neutralizing antibody titers IC of YK-RSV-061, YK-RSV-003 and YK-RSV-062 50 For Abrysvo TM 4.51 ~7.57 times of the positive control, IC 90 For Abrysvo TM 8.75~11.56 times that of the positive control.
[0635] Among them, YK-RSV-061 IC 50 It's Abrysvo TM 7.57 times of the positive control, IC 90 The neutralizing antibody titer was 11.56 times that of the positive control.
[0636]
[0637] .
[0638] In summary, on days 42 and 48 after immunization of cotton rats, the binding antibody and neutralizing antibody titers produced by all test substances were significantly higher than those of the control Abrysvo TM , the humoral immune effect was significantly improved. Among them, the test substance YK-RSV-061 had the best immune effect. All the test substances also had good immune effects against different subtypes of viruses (including RSV A and B).
[0639] 2.7.3 Pathological sections of cotton rat lungs
[0640] Pathological sections of cotton rat lungs Fig.18 The scoring results are shown in the following table:
[0641] .
[0642] From the above results, it can be seen that the peribronchiolar infiltration scores of the test substances were all between 0.33 and 0.83, indicating mild inflammatory infiltration.
[0643] The interstitial invasion scores of all tested substances were better than those of the positive control Abrysvo TM , the score was 0.67~1.17, which was mild inflammatory infiltration.
[0644] The overall inflammatory response scores of all the test substances were low, and the total pathological scores were between 1.00 and 2.00, which were lower than the control LNP. Among them, the scores of perivascular infiltration and alveolar infiltration of the control and the test substances were both 0, and there were no visible lesions in the tissue.
[0645] 2.7.4 Results of viral load in cotton rat lungs and nasal turbinates
[0646] After the cotton rats were killed on the 54th day, the lung and nasal turbinates were aseptically collected for virus titer determination. The test results are shown in the following table.
[0647] .
[0648] The viral load in the lungs of cotton rats was measured, and the results showed that the viral load in the tissues after negative control LNP immunization was 4.52, which was significantly higher than that in the positive control Abrysvo TM and other test substances. Among them, the control Abrysvo TM The viral load in tissues after immunization was 2.14, while the viral load in tissues of other test substances after immunization was 1.61-2.08, which was lower than the positive control Abrysvo TM .
[0649] The viral load of cotton rat nasal turbinates was measured, and the results showed that the viral load of negative control LNP immunization tissue was 4.12, which was significantly higher than that of other test substances. TM The viral load of tissue after immunization was 3.35, and the viral load of tissue after immunization of other test substances was 0.62~1.51, only the positive control Abrysvo TM The viral load was significantly reduced, indicating that the test substance had a good antiviral effect.
[0650] 2.8 Mutant difference analysis
[0651] In summary, the present invention designed 52 antigen sequences encoding RSV F protein mutants, and screened out at least 11 (YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, YK-RSV-039, YK-RSV-044, YK-RSV-012, YK-RSV-015, YK-RSV-001, YK-RSV-036, and YK-RSV-060), especially at least 5 of them (YK-RSV-061, YK-RSV-003, YK-RSV-062, YK-RSV-054, and YK-RSV-039) that were better than the positive control Abrysvo. TM And the designed control PC-RSV-063, PC-RSV-064, PC-RSV-065, PC-RSV-066, PC-RSV-067, and PC-RSV-068 all have excellent antigen sequences. (1)
[0653]
[0654]
[0655]
[0656] .
[0657] Compared with the YK-RSV-003 mutant, YK-RSV-061 added one more mutation V152I; YK-RSV-062 added five more mutations C69Y, D73E, A74V, N88S and V152I;
[0658] The epitopes on the three mutants, YK-RSV-003, YK-RSV-061 and YK-RSV-062, all had good binding levels with the corresponding antibodies. For example, the binding level of the Quaternary epitope on YK-RSV-061, YK-RSV-003 and YK-RSV-062 to RSVpre-F antibody (7H11) was 2.01 to 2.12 times that of the control PC-RSV-064.
[0659] However, for RSV A virus, the neutralizing antibody titer IC 50 and IC 90 Up to Abrysvo TM The neutralizing antibody titers of YK-RSV-003 were 12.67 and 14.41 times of those of the positive control, while the IC 50 and IC 90 AbrysvoTM The neutralizing antibody titer of YK-RSV-061 was significantly increased, which was an unexpected result. The neutralizing antibody titer of YK-RSV-062 was equivalent to that of YK-RSV-003. Similarly, the neutralizing antibody titer of YK-RSV-061 also had a significant advantage against RSV B virus. (2)
[0661]
[0662] .
[0663] .
[0664] .
[0665] Compared with the YK-RSV-003 mutant, the control PC-RSV-063 changed one mutation type in group 2 of site mutation, replacing V296I with V207L; and deleted the D486S site mutation in group 3 of site mutation. However, the binding level of the Quaternary epitope on YK-RSV-003 with RSV pre-F antibody (7H11) was 2.04 times that of the control PC-RSV-063, and the difference in binding level was significant.
[0666] Compared with the YK-RSV-061 mutant, the control PC-RSV-065 and PC-RSV-066 reduced one site mutation (D486S or V296I), the control PC-RSV-064 reduced two site mutations (D486S and V296I), and the control PC-RSV-067 and PC-RSV-068 changed the mutation type in group 1 in the site mutation. The results showed that the affinity constant K of the Φ epitope on the YK-RSV-061 mutant binding to the RSV pre-F antibody (3C12) D The affinity constant K of the Quaternary epitope binding to RSV pre-F antibody (7H11) is 6.21E-11 M. D is 3.05E-12 M, and the K of other controls D The values were all E-10 M, with a difference of 1 to 2 orders of magnitude, indicating that the affinity of antigen YK-RSV-061 and antibody were higher than those of other controls.
[0667] From the above comparison, it can be seen that the binding level and binding force of the epitope on the YK-RSV-003 mutant to the corresponding antibody are significantly higher than those of the control PC-RSV-063~PC-RSV-068; at the same time, combined with the comparison results in part (1), the effect of the YK-RSV-061 mutant is significantly better than that of the YK-RSV-003 mutant, and the effect of YK-RSV-062 is equivalent to that of YK-RSV-003. Therefore, YK-RSV-061, YK-RSV-003 and YK-RSV-062 are all better than the control PC-RSV-063~PC-RSV-068.
[0668] The following table shows the complete sequence information and its numbering of this application, taking the antigen sequence of YK-RSV-001 as an example, wherein SEQ NO ID: 3 and 4 are the DNA sequence and amino acid sequence of the open reading frame of antigen YK- RSV -001, respectively; SEQ NO ID: 2 and 5 are the DNA sequence and mRNA sequence of antigen YK- RSV -001, respectively.
[0669]
[0670]
[0671]
[0672]
[0673]
[0674] .
[0675] All sequences in this disclosure are listed below:
[0676] RSV A2 (138251)-wt SEQ ID NO: 1
[0677] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPPTNRRARRELPRFMNYTLNNAKKTNVTLSKRKRRFLGFLLG VGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLEITREFSVNAGVTTPVSTYMLTNSELLSLINMPITNDQKKLMSNNVQIVRQQSYS IMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEINLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKTASNKNRG IIKTFSNGCDYVSNKGMDTVSVGNTLYYVNKQEGKSLYVKGEPIINFDYPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLYKARSTPVTLSKDQLSGINNIAFSN
[0678] 2. YK-RSV-001 DNA, SEQ ID NO: 2
[0679]
[0680] 3. YK-RSV-001 ORF NT, SEQ ID NO: 3
[0681]
[0682] 4. YK-RSV-001 ORF AA, SEQ ID NO: 4
[0683] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTIKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0684] 5. YK-RSV-001 mRNA, SEQ ID NO: 5
[0685]
[0686] 6. YK-RSV-002 DNA, SEQ ID NO: 6
[0687]
[0688] 7. YK-RSV-002 ORF NT, SEQ ID NO: 7
[0689]
[0690] 8. YK-RSV-002 ORF AA, SEQ ID NO: 8
[0691] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYHSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0692] 9. YK-RSV-002 mRNA, SEQ ID NO: 9
[0693]
[0694] 10. YK-RSV-003 DNA, SEQ ID NO: 10
[0695]
[0696] 11. YK-RSV-003 ORF NT, SEQ ID NO: 11
[0697]
[0698] 12. YK-RSV-003 ORF AA, SEQ ID NO: 12
[0699] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEILAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0700] 13 YK-RSV-003 mRNA, SEQ ID NO: 13
[0701]
[0702] 14. YK-RSV-004 DNA, SEQ ID NO: 14
[0703]
[0704] 15. YK-RSV-004 ORF NT, SEQ ID NO: 15
[0705]
[0706] 16. YK-RSV-004 ORF AA, SEQ ID NO: 16
[0707] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTIKVLDLKNYIDKQLLPIVNKQSCPISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0708] 17. YK-RSV-004 mRNA, SEQ ID NO: 17
[0709]
[0710] 18. YK-RSV-005 DNA, SEQ ID NO: 18
[0711]
[0712] 19. YK-RSV-005 ORF NT, SEQ ID NO: 19
[0713]
[0714] 20. YK-RSV-005 ORF AA, SEQ ID NO: 20
[0715] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTIKVLDLKNYIDKQLLPIVNKQSCSISPIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0716] 21. YK-RSV-005 mRNA, SEQ ID NO: 21
[0717]
[0718] 22. YK-RSV-008 DNA, SEQ ID NO: 22
[0719]
[0720] 23. YK-RSV-008 ORF NT, SEQ ID NO: 23
[0721]
[0722] 24. YK-RSV-008 ORF AA, SEQ ID NO: 24
[0723] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTIKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0724] 25. YK-RSV-008 mRNA, SEQ ID NO: 25
[0725]
[0726] 26. YK-RSV-009 DNA, SEQ ID NO: 26
[0727]
[0728] 27. YK-RSV-009 ORF NT, SEQ ID NO: 27
[0729]
[0730] 28. YK-RSV-009 ORF AA, SEQ ID NO: 28
[0731] MELLILKANAITTILTAVTFCFASGQNITEEFYCSTCSAVSKGYLGALRTGWYTSVILIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKCEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0732] 29. YK-RSV-009 mRNA, SEQ ID NO: 29
[0733]
[0734] 30. YK-RSV-010 DNA, SEQ ID NO: 30
[0735]
[0736] 31. YK-RSV-010 ORF NT, SEQ ID NO: 31
[0737]
[0738] 32. YK-RSV-010 ORF AA, SEQ ID NO: 32
[0739] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVILIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0740] 33. YK-RSV-010 mRNA, SEQ ID NO: 33
[0741]
[0742] 34. YK-RSV-011 DNA, SEQ ID NO: 34
[0743]
[0744] 35. YK-RSV-011 ORF NT, SEQ ID NO: 35
[0745]
[0746] 36. YK-RSV-011 ORF AA, SEQ ID NO: 36
[0747] MELLILKANAITTILTAVTFCFASGQNITEEFYCSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIEIVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKCEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0748] 37. YK-RSV-011 mRNA, SEQ ID NO: 37
[0749]
[0750] 38. YK-RSV-012 DNA, SEQ ID NO: 38
[0751]
[0752] 39. YK-RSV-012 ORF NT, SEQ ID NO: 39
[0753]
[0754] 40. YK-RSV-012 ORF AA, SEQ ID NO: 40
[0755] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTFKVLDLKNYIDKQLLPIVNKQSCSIPNIEIVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0756] 41. YK-RSV-012 mRNA, SEQ ID NO: 41
[0757]
[0758] 42. YK-RSV-013 DNA, SEQ ID NO: 42
[0759]
[0760] 43. YK-RSV-013 ORF NT, SEQ ID NO: 43
[0761]
[0762] 44. YK-RSV-013 ORF AA, SEQ ID NO: 44
[0763] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPACGSGSACASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0764] 45. YK-RSV-013 mRNA, SEQ ID NO: 45
[0765]
[0766] 46. YK-RSV-014 DNA, SEQ ID NO: 46
[0767]
[0768] 47. YK-RSV-014 ORF NT, SEQ ID NO: 47
[0769]
[0770] 48. YK-RSV-014 ORF AA, SEQ ID NO: 48
[0771] MELLILKANAITTILTAVTFCFASGQNITEEFYCSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTIKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKCEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0772] 49. YK-RSV-014 mRNA, SEQ ID NO: 49
[0773]
[0774] 50. YK-RSV-015 DNA, SEQ ID NO: 50
[0775]
[0776] 51. YK-RSV-015 ORF NT, SEQ ID NO: 51
[0777]
[0778] 52. YK-RSV-015 ORF AA, SEQ ID NO: 52
[0779] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTIKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0780] 53. YK-RSV-015 mRNA, SEQ ID NO: 53
[0781]
[0782] 54. YK-RSV-016 DNA, SEQ ID NO: 54
[0783]
[0784] 55. YK-RSV-016 ORF NT, SEQ ID NO: 55
[0785]
[0786] 56. YK-RSV-016 ORF AA, SEQ ID NO: 56
[0787] MELLILKANAITTILTAVTFCFASGQNITEEFYCSTCSAVSKGYLGALRTGWYTSVILIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKCEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0788] 57. YK-RSV-016 mRNA, SEQ ID NO: 57
[0789]
[0790] 58. YK-RSV-017 DNA, SEQ ID NO: 58
[0791]
[0792] 59. YK-RSV-017 ORF NT, SEQ ID NO: 59
[0793]
[0794] 60. YK-RSV-017 ORF AA, SEQ ID NO: 60
[0795] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVILIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0796] 61. YK-RSV-017 mRNA, SEQ ID NO: 61
[0797]
[0798] 62. YK-RSV-018 DNA, SEQ ID NO: 62
[0799]
[0800] 63. YK-RSV-018 ORF NT, SEQ ID NO: 63
[0801]
[0802] 64. YK-RSV-018 ORF AA, SEQ ID NO: 64
[0803] MELLILKANAITTILTAVTFCFASGQNITEEFYCSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIEIVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKCEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0804] 65. YK-RSV-018 mRNA, SEQ ID NO: 65
[0805]
[0806] 66. YK-RSV-019 DNA, SEQ ID NO: 66
[0807]
[0808] 67. YK-RSV-019 ORF NT, SEQ ID NO: 67
[0809]
[0810] 68. YK-RSV-019 ORF AA, SEQ ID NO: 68
[0811] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTFKVLDLKNYIDKQLLPIVNKQSCSIPNIEIVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0812] 69. YK-RSV-019 mRNA, SEQ ID NO: 69
[0813]
[0814] 70. YK-RSV-022 DNA, SEQ ID NO: 70
[0815]
[0816] 71. YK-RSV-022 ORF NT, SEQ ID NO: 71
[0817]
[0818] 72. YK-RSV-022 ORF AA, SEQ ID NO: 72
[0819] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPACGSGSACASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSGCGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKCRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0820] 73. YK-RSV-022 mRNA, SEQ ID NO: 73
[0821]
[0822] 74. YK-RSV-029 DNA, SEQ ID NO: 74
[0823]
[0824] 75. YK-RSV-029 ORF NT, SEQ ID NO: 75
[0825]
[0826] 76. YK-RSV-029 ORF AA, SEQ ID NO: 76
[0827] MELLILKANAITTILTAVTFCFASGQNICEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGCSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0828] 77. YK-RSV-029 mRNA, SEQ ID NO: 77
[0829]
[0830] 78. YK-RSV-030 DNA, SEQ ID NO: 78
[0831]
[0832] 79. YK-RSV-030 ORF NT, SEQ ID NO: 79
[0833]
[0834] 80. YK-RSV-030 ORF AA, SEQ ID NO: 80
[0835] MELLILKANAITTILTAVTFCFASGQNITECFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSCYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0836] 81. YK-RSV-030 mRNA, SEQ ID NO: 81
[0837]
[0838] 82. YK-RSV-031 DNA, SEQ ID NO: 82
[0839]
[0840] 83. YK-RSV-031 ORF NT, SEQ ID NO: 83
[0841]
[0842] 84. YK-RSV-031 ORF AA, SEQ ID NO: 84
[0843] MELLILKANAITTILTAVTFCFASGQNITEECYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLCVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0844] 85. YK-RSV-031 mRNA, SEQ ID NO: 85
[0845]
[0846] 86. YK-RSV-032 DNA, SEQ ID NO: 86
[0847]
[0848] 87. YK-RSV-032 ORF NT, SEQ ID NO: 87
[0849]
[0850] 88. YK-RSV-032 ORF AA, SEQ ID NO: 88
[0851] MELLILKANAITTILTAVTFCFASGQNITEEFYCSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVCGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0852] 89. YK-RSV-032 mRNA, SEQ ID NO: 89
[0853]
[0854] 90. YK-RSV-033 DNA, SEQ ID NO: 90
[0855]
[0856] 91. YK-RSV-033 ORF NT, SEQ ID NO: 91
[0857]
[0858] 92. YK-RSV-033 ORF AA, SEQ ID NO: 92
[0859] MELLILKANAITTILTAVTFCFASGQNITEEFYQSCCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKCEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0860] 93. YK-RSV-033 mRNA, SEQ ID NO: 93
[0861]
[0862] 94. YK-RSV-034 DNA, SEQ ID NO: 94
[0863]
[0864] 95. YK-RSV-034 ORF NT, SEQ ID NO: 95
[0865]
[0866] 96. YK-RSV-034 ORF AA, SEQ ID NO: 96
[0867] MELLILKANAITTILTAVTFCFASGCNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNCQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0868] 97. YK-RSV-034 mRNA, SEQ ID NO: 97
[0869]
[0870] 98. YK-RSV-035 DNA, SEQ ID NO: 98
[0871]
[0872] 99. YK-RSV-035 ORF NT, SEQ ID NO: 99
[0873]
[0874] 100. YK-RSV-035 ORF AA, SEQ ID NO: 100
[0875] MELLILKANAITTILTAVTFCFASGQCITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKCEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0876] 101. YK-RSV-035 mRNA, SEQ ID NO: 101
[0877]
[0878] 102. YK-RSV-036 DNA, SEQ ID NO: 102
[0879]
[0880] 103. YK-RSV-036 ORF NT, SEQ ID NO: 103
[0881]
[0882] 104. YK-RSV-036 ORF AA, SEQ ID NO: 104
[0883] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVACSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0884] 105. YK-RSV-036 mRNA, SEQ ID NO: 105
[0885]
[0886] 106. YK-RSV-037 DNA, SEQ ID NO: 106
[0887]
[0888] 107. YK-RSV-037 ORF NT, SEQ ID NO: 107
[0889]
[0890] 108. YK-RSV-037 ORF AA, SEQ ID NO: 108
[0891] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWCTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVCVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0892] 109 YK-RSV-037 mRNA, SEQ ID NO: 109
[0893]
[0894] 110. YK-RSV-038 DNA, SEQ ID NO: 110
[0895]
[0896] 111. YK-RSV-038 ORF NT, SEQ ID NO: 111
[0897]
[0898] 112. YK-RSV-038 ORF AA, SEQ ID NO: 112
[0899] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVCVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0900] 113. YK-RSV-038 mRNA, SEQ ID NO: 113
[0901]
[0902] 114. YK-RSV-039 DNA, SEQ ID NO: 114
[0903]
[0904] 115. YK-RSV-039 ORF NT, SEQ ID NO: 115
[0905]
[0906] 116. YK-RSV-039 ORF AA, SEQ ID NO: 116
[0907] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYCSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGCAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0908] 117. YK-RSV-039 mRNA, SEQ ID NO: 117
[0909]
[0910] 118. YK-RSV-040 DNA, SEQ ID NO: 118
[0911]
[0912] 119. YK-RSV-040 ORF NT, SEQ ID NO: 119
[0913]
[0914] 120. YK-RSV-040 ORF AA, SEQ ID NO: 120
[0915] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYCSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVCVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0916] 121. YK-RSV-040 mRNA, SEQ ID NO: 121
[0917]
[0918] 122. YK-RSV-041 DNA, SEQ ID NO: 122
[0919]
[0920] 123. YK-RSV-041 ORF NT, SEQ ID NO: 123
[0921]
[0922] 124. YK-RSV-041 ORF AA, SEQ ID NO: 124
[0923] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVCKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTCPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0924] 125. YK-RSV-041 mRNA, SEQ ID NO: 125
[0925]
[0926] 126. YK-RSV-042 DNA, SEQ ID NO: 126
[0927]
[0928] 127. YK-RSV-042 ORF NT, SEQ ID NO: 127
[0929]
[0930] 128. YK-RSV-042 ORF AA, SEQ ID NO: 128
[0931] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGCLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTCPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0932] 129. YK-RSV-042 mRNA, SEQ ID NO: 129
[0933]
[0934] 130. YK-RSV-043 DNA, SEQ ID NO: 130
[0935]
[0936] 131. YK-RSV-043 ORF NT, SEQ ID NO: 131
[0937]
[0938] 132. YK-RSV-043 ORF AA, SEQ ID NO: 132
[0939] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSCPATGSGSAIACGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0940] 133. YK-RSV-043 mRNA, SEQ ID NO: 133
[0941]
[0942] 134. YK-RSV-044 DNA, SEQ ID NO: 134
[0943]
[0944] 135. YK-RSV-044 ORF NT, SEQ ID NO: 135
[0945]
[0946] 136. YK-RSV-044 ORF AA, SEQ ID NO: 136
[0947] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSCPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0948] 137. YK-RSV-044 mRNA, SEQ ID NO: 137
[0949]
[0950] 138. YK-RSV-045 DNA, SEQ ID NO: 138
[0951]
[0952] 139. YK-RSV-045 ORF NT, SEQ ID NO:139
[0953]
[0954] 140. YK-RSV-045 ORF AA, SEQ ID NO: 140
[0955] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSCPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYCVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0956] 141. YK-RSV-045 mRNA, SEQ ID NO: 141
[0957]
[0958] 142. YK-RSV-046 DNA, SEQ ID NO: 142
[0959]
[0960] 143. YK-RSV-046 ORF NT, SEQ ID NO: 143
[0961]
[0962] 144. YK-RSV-046 ORF AA, SEQ ID NO: 144
[0963] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSFCGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRCDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0964] 145. YK-RSV-046 mRNA, SEQ ID NO: 145
[0965]
[0966] 146. YK-RSV-047 DNA, SEQ ID NO: 146
[0967]
[0968] 147. YK-RSV-047 ORF NT, SEQ ID NO: 147
[0969]
[0970] 148. YK-RSV-047 ORF AA, SEQ ID NO: 148
[0971] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSFLCFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPCAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0972] 149. YK-RSV-047 mRNA, SEQ ID NO: 149
[0973]
[0974] 150. YK-RSV-048 DNA, SEQ ID NO: 150
[0975]
[0976] 151. YK-RSV-048 ORF NT, SEQ ID NO: 151
[0977]
[0978] 152. YK-RSV-048 ORF AA, SEQ ID NO: 152
[0979] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSFLGFLCGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMCSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0980] 153. YK-RSV-048 mRNA, SEQ ID NO: 153
[0981]
[0982] 154. YK-RSV-049 DNA, SEQ ID NO: 154
[0983]
[0984] 155. YK-RSV-049 ORF NT, SEQ ID NO: 155
[0985]
[0986] 156. YK-RSV-049 ORF AA, SEQ ID NO: 156
[0987] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSFLGFLLGVCSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTCNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0988] 157. YK-RSV-049 mRNA, SEQ ID NO: 157
[0989]
[0990] 158. YK-RSV-050 DNA, SEQ ID NO: 158
[0991]
[0992] 159. YK-RSV-050 ORF NT, SEQ ID NO: 159
[0993]
[0994] 160. YK-RSV-050 ORF AA, SEQ ID NO: 160
[0995] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSFLGFCLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMCSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[0996] 161. YK-RSV-050 mRNA, SEQ ID NO: 161
[0997]
[0998] 162. YK-RSV-051 DNA, SEQ ID NO: 162
[0999]
[1000] 163. YK-RSV-051 ORF NT, SEQ ID NO: 163
[1001]
[1002] 164. YK-RSV-051 ORF AA, SEQ ID NO: 164
[1003] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSFLGCLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDCMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1004] 165. YK-RSV-051 mRNA, SEQ ID NO: 165
[1005]
[1006] 166. YK-RSV-052 DNA, SEQ ID NO: 166
[1007]
[1008] 167. YK-RSV-052 ORF NT, SEQ ID NO: 167
[1009]
[1010] 168 YK-RSV-052 ORF AA, SEQ ID NO: 168
[1011] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGCAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPCYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1012] 169. YK-RSV-052 mRNA, SEQ ID NO: 169
[1013]
[1014] 170. YK-RSV-053 DNA, SEQ ID NO: 170
[1015]
[1016] 171. YK-RSV-053 ORF NT, SEQ ID NO: 171
[1017]
[1018] 172. YK-RSV-053 ORF AA, SEQ ID NO: 172
[1019] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLCGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1020] 173. YK-RSV-053 mRNA, SEQ ID NO: 173
[1021]
[1022] 174. YK-RSV-054 DNA, SEQ ID NO: 174
[1023]
[1024] 175. YK-RSV-054 ORF NT, SEQ ID NO: 175
[1025]
[1026] 176. YK-RSV-054 ORF AA, SEQ ID NO: 176
[1027] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSACASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSCMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1028] 177. YK-RSV-054 mRNA, SEQ ID NO: 177
[1029]
[1030] 178. YK-RSV-055 DNA, SEQ ID NO: 178
[1031]
[1032] 179. YK-RSV-055 ORF NT, SEQ ID NO: 179
[1033]
[1034] 180. YK-RSV-055 ORF AA, SEQ ID NO: 180
[1035] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSCIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSICKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1036] 181. YK-RSV-055 mRNA, SEQ ID NO: 181
[1037]
[1038] 182. YK-RSV-056 DNA, SEQ ID NO: 182
[1039]
[1040] 183. YK-RSV-056 ORF NT, SEQ ID NO: 183
[1041]
[1042] 184. YK-RSV-056 ORF AA, SEQ ID NO: 184
[1043] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSCIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYCIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1044] 185. YK-RSV-056 mRNA, SEQ ID NO: 185
[1045]
[1046] 186. YK-RSV-057 DNA, SEQ ID NO: 186
[1047]
[1048] 187. YK-RSV-057 ORF NT, SEQ ID NO: 187
[1049]
[1050] 188. YK-RSV-057 ORF AA, SEQ ID NO: 188
[1051] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSCIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSCIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1052] 189. YK-RSV-057 mRNA, SEQ ID NO: 189
[1053]
[1054] 190. YK-RSV-058 DNA, SEQ ID NO: 190
[1055]
[1056] 191. YK-RSV-058 ORF NT, SEQ ID NO: 191
[1057]
[1058] 192. YK-RSV-058 ORF AA, SEQ ID NO: 192
[1059] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGCNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKCEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1060] 193. YK-RSV-058 mRNA, SEQ ID NO: 193
[1061]
[1062] 194. YK-RSV-059 DNA, SEQ ID NO: 194
[1063]
[1064] 195. YK-RSV-059 ORF NT, SEQ ID NO: 195
[1065]
[1066] 196. YK-RSV-059 ORF AA, SEQ ID NO: 196
[1067] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTCTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKCEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1068] 197. YK-RSV-059 mRNA, SEQ ID NO: 197
[1069]
[1070] 198. YK-RSV-060 DNA, SEQ ID NO: 198
[1071]
[1072] 199. YK-RSV-060 ORF NT, SEQ ID NO: 199
[1073]
[1074] 200. YK-RSV-060 ORF AA, SEQ ID NO: 200
[1075] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDCGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPCEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1076] 201. YK-RSV-060 mRNA, SEQ ID NO: 201
[1077]
[1078] 202. YK-RSV-061 DNA, SEQ ID NO: 202
[1079]
[1080] 203. YK-RSV-061 ORF NT, SEQ ID NO: 203
[1081]
[1082] 204. YK-RSV-061 ORF AA, SEQ ID NO: 204
[1083] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGIAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEILAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1084] 205. YK-RSV-061 mRNA, SEQ ID NO: 205
[1085]
[1086] 206. YK-RSV-062 DNA, SEQ ID NO: 206
[1087]
[1088] 207. YK-RSV-062 ORF NT, SEQ ID NO: 207
[1089]
[1090] 208. YK-RSV-062 ORF AA, SEQ ID NO: 208
[1091] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKYNGTEVKVKLIKQELDKYKSAVTDLQLLMQSTPATGSGSAICSGIAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEILAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1092] 209. YK-RSV-062 mRNA, SEQ ID NO: 209
[1093]
[1094] 210. RSV A2 (138251)-mt SEQ ID NO: 210
[1095] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN
[1096] 211. PC-RSV-063 SEQ ID NO: 211
[1097] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1098] 212. PC-RSV-064 SEQ ID NO: 212
[1099] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGIAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1100] 213. PC-RSV-065 SEQ ID NO: 213
[1101] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGIAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEILAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1102] 214. PC-RSV-066 SEQ ID NO: 214
[1103] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGIAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1104] 215. PC-RSV-067 SEQ ID NO: 215
[1105] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPACGSGSACASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEILAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1106] 216. PC-RSV-068 SEQ ID NO: 216
[1107] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLGALRTGWYTCVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGIAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVCTFKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEILAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGQSLYVKGEPIINFYDPLVFPSSEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLY
[1108] 217. 5’ UTR SEQ ID NO: 217
[1109] 5’AGCGGCTCGGCCATTTTGTCCCAGTCAGTCCGGAGGCTGCGGCTGCAGAAGTACCGCCTGCGGAGTAACTGCAAAGGCCACC3’
[1110] 218. 5’ UTR SEQ ID NO: 218
[1111] 5’AGACTCCTCCCCATCCTCTCCCTCTGTCCCTCTGTCCCTCTGACCCTGCACTGTCCCAGCACCGCCACC3’
[1112] 219. 5’ UTR SEQ ID NO: 219
[1113] 5’GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGACCCCGGCGCCGCCACC3’
[1114] 220. 5’ UTR SEQ ID NO: 220
[1115] 5’GAGAATAAACTAGTATTCTTCTGGTCCCCACAGACTCAGAGAGAACCCGCCACC3’
[1116] 221. 5’ UTR SEQ ID NO: 221
[1117] 5'GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC3’
[1118] 222. 3’ UTR SEQ ID NO: 222
[1119] 5’GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC3’;
[1120] 223. 3’ UTR SEQ ID NO: 223
[1121] 5’GCTGGAGCCTCGGTGGCCTAGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC3’;
[1122] 224. 3’ UTR SEQ ID NO: 224
[1123] 5’CTCGAGCTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGCTAGTTCCAGACACCTCCCAAGCACGCAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACCCTGGAGCTAGC3’;
[1124] 225. 3’ UTR SEQ ID NO: 225
[1125] 5’TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGA3’。
Claims
1. An immunogenic composition comprising ribonucleic acid (RNA) of respiratory syncytial virus (RSV), wherein the RNA encodes a wild-type RSV F protein variant; The sequence of the wild-type RSV F protein is SEQ ID NO: 1; The RSV F protein variant comprises P102A, I379V and M447V mutations, and the RSV F protein variant is a truncated protein after the amino acids 550-574 in SEQ ID NO: 1 are truncated, and the amino acids 104-144 are replaced with a GS linker, and the RSV F protein variant further comprises a site mutation combination selected from any one of the following groups 1 to 5, thereby obtaining an RSV F protein variant selected from YK-RSV-061, YK-RSV-003 and / or YK-RSV-062:
2. The composition of claim 1, wherein the amino acid sequence of the RSV F protein variant is: SEQ ID NO: 204, SEQ ID NO: 12 or SEQ ID NO:
208.
3. A composition as described in claim 1, wherein the nucleotide sequence of the open reading frame (ORF) encoding the RSV F protein variant is: SEQ ID NO:203, SEQ ID NO:11 or SEQ ID NO:
207.
4. The composition of claim 1, wherein the RNA of RSV further comprises a 5' untranslated region (UTR).
5. The composition of claim 4, wherein the sequence of the 5' untranslated region is: SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220 or SEQ ID NO:
221.
6. The composition of claim 1, wherein the RNA of RSV further comprises a 3' untranslated region (UTR).
7. The composition of claim 6, wherein the sequence of the 3' untranslated region is: SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224 or SEQ ID NO:
225.
8. The composition of claim 1, wherein the RNA of the RSV further comprises a poly(A) tail.
9. The composition of claim 8, wherein the Ploy(A) tail has a length of 50 to 150 nucleotides.
10. The composition of claim 1, wherein the RSV RNA further comprises a 5'-terminal cap structure.
11. The composition of claim 10, wherein the 5' end cap structure is: 7mG(5')ppp(5')NlmpNp.
12. The composition of claim 1, wherein the sequence of the open reading frame (ORF) encoding the RSV F protein or a variant thereof in the RSV RNA is codon optimized.
13. The composition of claim 12, wherein the sequence of the ORF comprises at least one base modification.
14. The composition of claim 13, wherein the base modification comprises any one or more selected from the group consisting of pseudouridine, N1-methyl pseudouridine, N1-ethyl pseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2′-O-methyluridine.
15. The composition of claim 14, wherein the base modification comprises replacing uracil with pseudouridine and / or N1-methylpseudouridine. The composition of claim 13 , wherein the base modification is 1% to 100% base modification.
17. The composition of claim 1, wherein the sequence of the RNA of RSV is: SEQ ID NO:205, SEQ ID NO:13 or SEQ ID NO:
209.
18. The composition of claim 1, wherein the DNA sequence encoding the RSV F protein variant is: SEQ ID NO: 202, SEQ ID NO: 10 or SEQ ID NO:
206.
19. A method for preparing a composition as claimed in any one of claims 1 to 18, comprising: Providing a template for transcribing the RSV RNA; The template is used for transcription under conditions suitable for transcribing the RNA.
20. The method according to claim 19, further comprising a purification step selected from the group consisting of lithium chloride precipitation, affinity chromatography, ultrafiltration, and cellulose chromatography.
21. The composition of claim 1 which is a vaccine and further comprises a pharmaceutically acceptable carrier.
22. The composition of claim 21, wherein the pharmaceutically acceptable carrier comprises a lipid mixture that is a lipid nanoparticle (LNP).
23. The composition of claim 21, wherein the vaccine is an mRNA vaccine.
24. The composition of claim 22, wherein the lipid nanoparticles comprise cationic lipids, neutral lipids, structural lipids, and polymer-conjugated lipids.
25. The composition of claim 24, wherein the cationic lipid is a compound of formula I, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G1 is C 1~6 Alkylene; G2 is C 2~8 Alkylene; G3 is C 1~3 Alkylene; L1 is C 6~15 Straight chain alkyl; L2 is C 12~25 Branched chain alkyl 26. The composition of claim 24, wherein the cationic lipid is a compound of formula II, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G1 is C 2~8 Alkylene; G2 is C 2~8 Alkylene; L1 is -C(O)O- or -OC(O)-; L2 is -C(O)O- or -OC(O)-; R1 is C 6~25 Straight or branched alkyl; R2 is C 6~25 Straight or branched alkyl; G3 is HO(CH2)2- or HO(CH2)3-; G4 is HO(CH2)2- or HO(CH2)3-; L is (CH2)2- or -(CH2)3- or -(CH2)4- 27. The composition of claim 24, wherein the cationic lipid is a compound of formula III, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G1 is C 1~6 Alkylene; G2 is C 2~8 Alkylene; R1 is C 6~20 Straight or branched alkyl; R2 is C 12~25 Branched alkyl; G3 is: HO(CH2)2N(CH3)(CH2)2-, HO(CH2)2N(CH2CH3)(CH2)2-, (HO(CH2)2)2N(CH2)2-, CH3O(CH2)2N(CH3)( CH2)2-, (CH3)2N(CH2)3SC(O)O(CH2)2-, (CH3)2N(CH2)3SC(O)-, CH3NH(CH2)2N(CH3)(CH2)2- or CH3CH2NH(CH2)2- 28. The composition of claim 24, wherein the cationic lipid is a compound of formula IV, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein G1 is C 1~8 Alkylene; G2 is C 2~8 Alkylene; R1 is C 6~25 Straight or branched alkyl; R2 is C 12~25 Straight or branched alkyl; G3 is HO(CH2)2N(R3)CH2CH(OH)CH2-, wherein R3 is -CH3 or -CH2CH3 or -CH2CH2OH 29. The composition of claim 24, wherein the cationic lipid is a compound of formula V, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein, G1 and G2 are each independently an unsubstituted C6-C 10 Alkylene; G3 is unsubstituted C1-C 12 Alkylene; R1 and R2 are each independently C6-C 24 Alkyl or C6-C 24 alkenyl; R3 is OR5, N, -C(=O)OR4, -OC(=O)R4 or -NR5C(=O)R4; R4 is C1-C 12 Alkyl; and R5 is H or C1-C6 alkyl 30. The composition of claim 24, wherein the cationic lipid is a compound of formula VI, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein: R4 is selected from -(CH2) n Q and -(CH2) n CHQR; Q is selected from the group consisting of: -OR, -OH, -O(CH2) n wherein n is 1, 2 or 3; wherein R is hydrogen, C(O) or C(S)R; wherein n is 1, 2 or 3; wherein R is hydrogen, C(O) or C(S)R; wherein n is 1, 2 or 3; wherein R is hydrogen, C(O) or C(S)R; wherein n is 1, 2 or 3; wherein R is hydrogen, C(O) or C(S)R; wherein n is 1, 2 or 3; wherein R is hydrogen, C(O) or C(S)R; wherein n is 1, 2 or 3; wherein R is hydrogen, C(O) or C(S) 1~3 Alkyl, C 2~3 Alkenyl or (CH2) q OR * , where q is 1, 2 or 3, R * C 1~12 Alkyl or C 2~12 alkenyl; X is fluorine, chlorine, bromine or iodine; R8 is C 3~6 Cycloalkyl or heterocyclic 31. The composition of claim 24, wherein the cationic lipid is a compound of formula VII, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof:
32. A composition as described in claim 24, wherein the cationic lipid is selected from the following compounds: YK-009, YK-401, YK-305, ALC0315, SM102, DLIN-MC3 33. The composition of claim 24, wherein the molar ratio of the cationic lipid to the neutral lipid is (1-10):
1.
34. The composition of claim 24, wherein the molar ratio of the cationic lipid to the structural lipid is (1-5):
1.
35. The composition of claim 24, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid and the polymer conjugated lipid is (25-75): (5-25): (15-65): (0.5-10).
36. The composition of claim 35, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid and the polymer conjugated lipid is (35-49): (7.5-15): (35-55): (1-5).
37. The composition of claim 24, wherein the neutral lipid is selected from one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol, and derivatives thereof.
38. The composition of claim 24, wherein the neutral lipid is selected from one or more of the following: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0Diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyl 1-stearoyl-2-oleoyl-stearoylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine and lysophosphatidylethanolamine (LPE).
39. The composition of claim 24, wherein the neutral lipid is DOPE and / or DSPC.
40. The composition of claim 24, wherein the structured lipid is selected from one or more of the following: cholesterol, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid, alpha-tocopherol, corticosteroids.
41. The composition of claim 40, wherein the structured lipid is cholesterol.
42. The composition of claim 24, wherein the polymer conjugated lipid is selected from one or more of the following: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol.
43. A composition as described in claim 42, wherein the polymer conjugated lipid is selected from one or more of the following: distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycerol-3-methoxy polyethylene glycol 2000 (DMG-PEG2000) and methoxy polyethylene glycol ditetradecanoyl acetamide (ALC-0159).
44. The composition of claim 21, wherein the effective dose of RSV RNA is 25 μg to 200 μg.
45. The composition of claim 21, wherein the effective dose of RSV RNA is 50 μg to 100 μg.
46. A composition as described in any one of claims 21 to 45, wherein the vaccine is in the form of an injectable dosage form.
47. A method for preparing a composition as claimed in any one of claims 21 to 46, comprising: The RSV RNA is mixed with the pharmaceutically acceptable carrier.
48. Use of the composition of any one of claims 1 to 18 and 21 to 46 in the preparation of a vaccine for inducing a protective immune response against RSV in a subject.
49. Use of the composition of any one of claims 1 to 18 and 21 to 46 in the preparation of a vaccine for inducing a humoral immune response against RSV in a subject.
50. Use of the composition of any one of claims 1 to 18 and 21 to 46 in the preparation of a vaccine for preventing RSV infection.
Citation Information
Patent Citations
Manufacturing methods for production of RNA transcripts
WO2014152027A1
Vaccine composition against two respiratory viruses
WO2023166079A1
Modified RSV F proteins and methods of their use
CN102307591A
Novel RSV RNA molecules and compositions for vaccination
CN112292395A
Mutant of RSV pre-fusion F protein, nucleic acid and mRNA vaccine
CN118206622A
Cited By
Respiratory syncytial virus mRNA vaccine, and preparation method therefor and use thereof
US12514920B1
